NantHealth (NHIQ) 10-Q 7 May 21 2021 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2021	May 07, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-37792
Entity Registrant Name	NantHealth, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-3019889
Entity Address, Address Line One	9920 Jefferson Blvd.
Entity Address, City or Town	Culver City,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90232
City Area Code	310
Local Phone Number	883-1300
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		113,400,267
Entity Central Index Key	0001566469
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 10,810	$ 22,787
Accounts receivable, net	4,705	3,273
Related party receivables, net	990	1,031
Prepaid expenses and other current assets	4,549	3,504
Total current assets	21,054	30,595
Property, plant, and equipment, net	12,859	13,102
Goodwill	98,333	98,333
Intangible assets, net	45,737	47,969
Related party receivable, net of current	858	823
Operating lease right-of-use assets	7,193	7,539
Other assets	1,932	1,927
Total assets	187,966	200,288
Current liabilities
Accounts payable	1,598	5,122
Accrued and other current liabilities	15,832	13,975
Deferred revenue	1,217	1,166
Related party payables, net	4,092	4,238
Related party convertible note, net	9,963	9,411
Convertible notes, net	96,095	90,578
Total current liabilities	128,797	124,758
Deferred revenue, net of current	611	393
Related party liabilities	32,860	31,091
Related party promissory note	112,666	112,666
Deferred income taxes, net	1,752	1,853
Operating lease liabilities	7,723	8,170
Other liabilities	35,198	32,757
Total liabilities	319,607	311,688
Commitments and Contingencies (Note 14)
Stockholders' deficit
Common stock, $0.0001 par value per share, 750,000,000 shares authorized; 111,366,133 and 111,284,733 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	11	11
Additional paid-in capital	878,241	891,583
Accumulated deficit	(1,010,046)	(1,003,210)
Accumulated other comprehensive loss	(140)	(168)
Total NantHealth stockholders' deficit	(131,934)	(111,784)
Noncontrolling interests	293	384
Total stockholders' deficit	(131,641)	(111,400)
Total liabilities and stockholders' deficit	187,966	200,288
Other Notes Payable, Current	$ 0	$ 268

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock authorized (shares)	750,000,000	750,000,000
Common stock issued (shares)	111,366,133	111,284,733
Common stock outstanding (shares)	111,366,133	111,284,733

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue
Revenue	$ 16,170	$ 18,180
Cost of Revenue:
Total cost of revenue	7,043	7,196
Gross Profit	9,127	10,984
Operating Expenses
Selling, general and administrative	12,502	12,427
Research and development	5,013	3,550
Amortization of acquisition-related assets	985	867
Total operating expenses	18,500	16,844
Loss from operations	(9,373)	(5,860)
Interest expense, net	(3,568)	(4,657)
Other (expense) income, net	(2,570)	3,454
Loss from related party equity method investment	0	(1,784)	[1]
Loss from continuing operations before income taxes	(15,511)	(8,847)
(Benefit from) provision for income taxes	(8)	93
Net loss from continuing operations	(15,503)	(8,940)
Income from discontinued operations, net of tax attributable to NantHealth	4	32,005
Net loss	(15,499)	23,065	[1]
Net loss attributable to noncontrolling interests	(91)	0
Net (loss) income attributable to NantHealth	$ (15,408)	$ 23,065
Basic and diluted net (loss) income per share attributable to NantHealth:
Continuing operations - common stock (in dollars per share)	$ (0.14)	$ (0.08)
Discontinued operations - common stock (in dollars per share)	0	0.29
Total net income (loss) per share - common stock (in dollars per share)	$ (0.14)	$ 0.21
Weighted average shares outstanding
Basic and diluted - common stock (shares)	111,319,061	110,619,780
Total software-related revenue
Revenue
Revenue	$ 16,167	$ 18,121
Cost of Revenue:
Total cost of revenue	6,996	6,844
Software-as-a-service related
Revenue
Revenue	15,757	18,121
Cost of Revenue:
Total cost of revenue	5,535	5,701
Maintenance
Revenue
Revenue	383	0
Cost of Revenue:
Total cost of revenue	207	0
Professional services
Revenue
Revenue	27	0
Cost of Revenue:
Total cost of revenue	7	0
Amortization of developed technologies
Cost of Revenue:
Total cost of revenue	1,247	1,143
Sequencing and molecular analysis
Revenue
Revenue	3	59
Cost of Revenue:
Total cost of revenue	$ 47	$ 352
[1]	The statements for the three months ended March 31, 2020 include the Connected Care Business (see Note 4).

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (15,499)	$ 23,065	[1]
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation adjustments	28	(188)
Other comprehensive loss	28	(188)
Comprehensive (loss) income	(15,471)	22,877
Less: Comprehensive loss attributable to noncontrolling interests	91	0
Comprehensive (loss) income attributable to NantHealth	$ (15,380)	$ 22,877
[1]	The statements for the three months ended March 31, 2020 include the Connected Care Business (see Note 4).

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total		Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-In Capital	Additional Paid-In CapitalCumulative Effect, Period of Adoption, Adjustment	Accumulated Deficit	Accumulated DeficitCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Total NantHealth Stockholders' Deficit	Total NantHealth Stockholders' DeficitCumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2019				110,619,678
Beginning balance at Dec. 31, 2019	$ (57,136)			$ 11	$ 889,955		$ (946,884)		$ (218)	$ (57,136)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation cost	668				668					668
Other comprehensive loss	(188)								(188)	(188)
Net loss	23,065	[1]					23,065			23,065
Ending balance (in shares) at Mar. 31, 2020				110,619,678
Ending balance at Mar. 31, 2020	(33,591)			$ 11	890,623		(923,819)		(406)	(33,591)		0
Beginning balance (in shares) at Dec. 31, 2020				111,284,733
Beginning balance at Dec. 31, 2020	(111,400)		$ (5,746)	$ 11	891,583	$ (14,318)	(1,003,210)	$ 8,572	(168)	(111,784)	$ (5,746)	384
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation cost	912				912					912
Shares issued in connection with employee stock plans, net of shares withheld for employee taxes (in shares)				81,400
Shares issued in connection with employee stock plans, net of shares withheld for employee taxes	64				64					64
Other comprehensive loss	28								28	28
Net loss	(15,499)						(15,408)			(15,408)		(91)
Ending balance (in shares) at Mar. 31, 2021				111,366,133
Ending balance at Mar. 31, 2021	$ (131,641)			$ 11	$ 878,241		$ (1,010,046)		$ (140)	$ (131,934)		$ 293
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	nant:AccountingStandardsUpdate2020-06
[1]	The statements for the three months ended March 31, 2020 include the Connected Care Business (see Note 4).

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020	[1]
Cash flows from operating activities:
Net loss		$ (15,499)	$ 23,065
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Gain on sale of businesses		0	(32,211)
Depreciation and amortization		3,803	4,271
Amortization of debt discounts and deferred financing offering cost		323	1,542
Change in fair value of derivatives liability		(4)	5
Change in fair value of Bookings Commitment		2,463	(3,128)
Stock-based compensation		887	653
Deferred income taxes, net		(101)	(227)
Provision for bad debt expense		11	6
Loss from related party equity method investment		0	1,784
Changes in operating assets and liabilities:
Accounts receivable, net		(1,443)	937
Inventories		0	(18)
Related party receivables, net		6	0
Prepaid expenses and other current assets		(48)	15,444
Accounts payable		(3,524)	(282)
Accrued and other current liabilities		1,833	(14,884)
Deferred revenue		269	(1,433)
Related party payables, net		1,652	1,937
Change in operating lease right-of-use assets and liabilities		(99)	(95)
Other assets and liabilities		(221)	(109)
Net cash used in operating activities		(9,692)	(2,743)
Cash flows from investing activities:
Net proceeds from sale of business		0	46,401
Purchases of property and equipment, including internal-use software		(1,141)	(935)
Net cash (used in) provided by investing activities		(1,141)	45,466
Cash flows from financing activities:
Repayments of insurance promissory note and notes payable		(268)	(238)
Proceeds from exercises of stock options		64	0
Net cash used in financing activities		(204)	(238)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		3	(11)
Net (decrease) increase in cash, cash equivalents and restricted cash		(11,034)	42,474
Cash, cash equivalents and restricted cash, beginning of period	[2]	24,162	6,379
Cash, cash equivalents and restricted cash, end of period	[2]	$ 13,128	$ 48,853
[1]	The statements for the three months ended March 31, 2020 include the Connected Care Business (see Note 4).
[2]	Cash and cash equivalents included restricted cash of $1,375 and $2,318 at December 31, 2020 and March 31, 2021, respectively, and $1,136 and $1,375 at December 31, 2019 and March 31, 2020, respectively. Restricted cash is included in prepaid expenses and other current assets and other assets and consists of funds that are contractually restricted as to usage or withdrawal related to the Company's performance bond related to a contract with a customer, security deposits in the form of standby letters of credit for leased facilities, and funds previously held in an escrow account related to the sale of the Connected Care Business (see Note 4). No amounts have been drawn upon the letters of credit as of March 31, 2021.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Statement of Cash Flows [Abstract]
Restricted cash	$ 2,318	$ 1,375	$ 1,375	$ 1,136

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Nature of Business Nant Health, LLC was formed on July 7, 2010, as a Delaware limited liability company. On June 1, 2016, Nant Health, LLC converted into a Delaware corporation (the “LLC Conversion”) and changed its name to NantHealth, Inc. (“NantHealth”). NantHealth, together with its subsidiaries (the “Company”), is a healthcare IT company converging science and technology. The Company works to transform clinical delivery with actionable clinical intelligence at the moment of decision, enabling clinical discovery through real-time machine learning systems. The Company markets certain of its solutions as a comprehensive integrated solution that includes its clinical decision support, payer engagement solutions, molecular sequencing and analysis services, data analysis and network monitoring and management. The Company also markets its clinical decision support, payer engagement solutions, molecular sequencing and analysis services, data analysis and network monitoring and management on a stand-alone basis. NantHealth is a majority-owned subsidiary of NantWorks, LLC (“NantWorks”), which is a subsidiary of California Capital Equity, LLC (“Cal Cap”). The three companies were founded by and are led by Dr. Patrick Soon-Shiong. On February 3, 2020, the Company sold certain of its assets related to its Connected Care Business (see Note 4). The divestiture enables the Company to focus on its core competencies of clinical decision support, payer engagement, molecular analysis, and data analytics. On July 22, 2020, the Company acquired The OpenNMS Group, Inc. ("OpenNMS") pursuant to an assignment agreement with Cambridge Equities, L.P. ("Cambridge"), a related party (see Note 19). The Company intends to integrate OpenNMS with NantHealth’s software portfolio and service offerings, as well as expand the Company’s capabilities in cloud, SaaS, and AI technologies, providing customers with services to maintain reliable network connections for critical data flows that enable patient data collaboration and decision making at the point of care. At the same time, this transaction will allow the Company to expand penetration of OpenNMS services in the healthcare industry. As of March 31, 2021, the Company conducted the majority of its operations in the United States, Canada, and the United Kingdom. COVID-19 Pandemic In March 2020, the World Health Organization declared the novel coronavirus (COVID-19) a pandemic. In the same month, the President of the United States declared a State of National Emergency due to the COVID-19 pandemic. Many jurisdictions, in North America (including the United States), Europe and Asia, have adopted or are considering laws, rules, regulations or decrees intended to address the COVID-19 pandemic, including implementing travel restrictions, closing non-essential businesses and/or restricting daily activities. In addition, many communities have limited social mobility and gathering. To date, there has been no material adverse impact to the Company's business from the COVID-19 pandemic. Given the unprecedented and evolving nature of the pandemic, the future impact of these changes and potential changes on the Company and its contractors, consultants, customers, resellers and partners is unknown at this time. However, in light of the uncertainties regarding economic, business, social, health and geopolitical conditions, the Company’s revenues, earnings, liquidity, and cash flows could be adversely affected, whether on an annual or quarterly basis. Continued impacts of the COVID-19 pandemic could materially adversely affect the Company’s current and long-term accounts receivable collectibility, as its negatively impacted customers from the pandemic may request temporary relief, delay, or not make scheduled payments. In addition, the deployment of the Company’s solutions may represent a large portion of its customers' investments in software technology. Decisions to make such an investment are impacted by the economic environment in which the customers operate. Uncertain global geopolitical, economic and health conditions and the lack of visibility or the lack of financial resources may cause some customers to reduce, postpone or terminate their investments, or to reduce or not renew ongoing paid services, adversely impacting the Company’s revenues or timing of revenue. Health conditions in some geographic areas where the Company’s customers operate could impact the economic situation of those areas. These conditions, including the COVID-19 pandemic, may present risks for health and limit the ability to travel for Company employees, which could further lengthen the Company’s sales cycle and delay revenue and cash flows in the near-term. For information on the CARES Act, refer to Note 15. Basis of Presentation and Principles of Consolidation The accompanying unaudited Consolidated Financial Statements include the accounts of NantHealth and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These interim Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company's financial position and results of operations. In accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X as issued by the Securities and Exchange Commission ("SEC"), these Consolidated Financial Statements do not include all of the information and disclosures required by GAAP for complete financial statements. These Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements for the fiscal year ended December 31, 2020. The results of operations of the entities disposed of are included in the unaudited Consolidated Financial Statements up to the date of disposal and, where appropriate, these operations have been reflected as discontinued operations. The accompanying Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited Consolidated Financial Statements at that date. Assets and liabilities of the discontinued operations are presented separately in the asset and liability sections of the prior period balance sheet. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year. The Company believes its existing cash, cash equivalents and its ability to borrow from affiliated entities will be sufficient to fund operations through at least 12 months following the issuance date of the financial statements. The Company continues to have its Chairman and CEO’s intent and ability to support the Company’s operations with additional funds as required. The Company may also seek to sell additional equity, through one or more follow-on public offerings or in separate financings, or sell additional debt securities, or obtain a credit facility. However, the Company may not be able to secure such financing in a timely manner or on favorable terms. The Company may also consider selling off components of its business. Without additional funds, the Company may choose to delay or reduce its operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of the Company's existing products as well as products in development, the Company may need additional funds to meet its needs sooner than planned. To date, the Company's primary sources of capital have been the private placement of membership interests prior to its IPO, debt financing agreements, including the promissory note with Nant Capital, LLC (“Nant Capital”) and its convertible notes, the sale of its common stock, and proceeds from the sale of components of its business.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates. Segment Reporting The chief operating decision maker for the Company is its Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, or plans for levels or components below the consolidated unit level. Ac cordingly, management has determined that the Company operates in one reportable segment. Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40) . This update simplifies the accounting for convertible instruments by eliminating the cash conversion and beneficial conversion feature models which require separate accounting for embedded conversion features. This update also amends the guidance for the derivatives scope exception for contracts in an entity's own equity to reduce form-over-substance-based accounting conclusions and requires the application of the if-converted method for calculating diluted earnings per share. ASU No. 2020-06 is effective for fiscal periods beginning after December 15, 2023. The Company early adopted ASU 2020-06 on a modified retrospective basis on January 1, 2021. The cumulative effect of the adoption on accumulated deficit and additional paid-in capital was a decrease of $8,572 and $14,318, respectively, on January 1, 2021. Under the new guidance, the Company will record less noncash interest expense going forward as the cash conversion model that was previously applied is now eliminated. Upcoming Accounting Standard Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments , which changes how companies measure credit losses on most financial instruments measured at amortized cost, such as loans, receivables and held-to-maturity debt securities. Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the Company expects to collect over the instrument's contractual life. ASU No. 2016-13 is effective for fiscal periods beginning after December 15, 2022 and must be adopted as a cumulative effect adjustment to retained earnings. Early adoption is permitted. The Company is still evaluating the effects of this ASU. In November 2020, the SEC issued Release No. 33-10890, Amendments to Management's Discussion and Analysis, Selected Financial Data, and Supplementary Financial Information , to modernize, simplify, and enhance certain financial disclosure requirements in Regulation S-K. Mandatory compliance for this SEC release is required for fiscal periods ending on or after August 9, 2021. The Company adopted Item 303(a)(5), Contractual Obligations , which no longer requires the registrant to provide a contractual obligation table. The Company’s adoption of the remaining items is expected to impact the Company's fiscal 2021 Form 10-K disclosures and will not have a material impact on the Consolidated Financial Statements. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not have, nor are believed by management to have, a material impact on the Company's present or future Consolidated Financial Statements.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Contract Balances The Company records deferred revenue when cash payments are received, or payment is due, in advance of its fulfillment of performance obligations. During the three months ended March 31, 2021 and 2020, there were revenues of $538 and $1,828 recognized, respectively, that were included in the deferred revenue balance at the beginning of the period. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company recognizes an asset for the incremental costs to obtain a contract with a customer, where the stated contract term, with expected renewals, is longer than one year. The Company amortizes these assets over the expected period of benefit. These costs are generally employee sales commissions, with amortization of the balance recorded in selling, general and administrative expenses. The value of these assets was $1,024 at March 31, 2021 and $1,321 at December 31, 2020. During the three months ended March 31, 2021 and 2020, the Company recorded amortization of $160 and $242, respectively. Where management is not able to conclude that the costs of a contract will be recovered, costs to obtain the contract are expensed as incurred. Remaining Performance Obligations As of March 31, 2021, the Company has allocated a total transaction price of $2,543 to unfulfilled performance obligations that are expected to be fulfilled within 10 years. Excluded from this amount are contracts of less than one year and variable consideration that relates to the value of services provided.

Discontinued Operations and Div

Discontinued Operations and Divestitures	3 Months Ended
	Mar. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations and Divestitures	Discontinued Operations and Divestitures Discontinued Operations Sale of Connected Care Business On January 13, 2020, the Company entered into an asset purchase agreement (the “Purchase Agreement”) with Masimo Corporation (“Masimo”), VCCB Holdings, Inc., a wholly owned subsidiary of Masimo (collectively with Masimo, the “Purchaser”), and, solely with respect to certain provisions of the Purchase Agreement, NantWorks, LLC, an affiliate of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchaser certain of its assets related to its Connected Care business, including the products known as DCX (formerly DeviceConX), VCX (formerly VitalsConX), HBox and Shuttle Cable (collectively, the “Connected Care Business”). On February 3, 2020, the Company completed the sale of the Connected Care Business for $47,250 of cash consideration in exchange for assets primarily related to the Connected Care Business (as defined under the terms of the Purchase Agreement). The sale of the Connected Care Business qualified as a discontinued operation because it comprised operations and cash flows that could be distinguished, operationally and for financial reporting purposes, from the rest of the Company. The disposal of the Connected Care Business, which represented the Company's medical device interoperability solutions, represented a strategic shift in the Company’s operations as the sale enables the Company to focus on clinical decision support, payer engagement, and molecular analysis. The total gain on sale of the Connected Care Business consisted of the following: Cash received as consideration $ 47,250 Less: Costs to sell (849) Less: Carrying value of net assets sold (14,190) Gain on sale of the Connected Care Business $ 32,211 The operating results of the Company's discontinued operation were as follows: Three Months Ended 2020 Major classes of line items constituting pretax income (loss) of discontinued operations Net revenue $ 1,165 Cost of revenue (467) Selling, general and administrative (524) Research and development (592) Other expense, net (5) Pretax loss from discontinued operations related to major classes of pretax income (loss) (423) Pretax gain on sale of the Connected Care Business 32,211 Total pretax income from discontinued operations 31,788 Benefit from income taxes (223) Total gain from discontinued operations, net of tax $ 32,011 The significant operating and investing cash and noncash items of the discontinued operation included on the Consolidated Statements of Cash Flows were as follows: Three Months Ended 2020 Cash flows from operating activities: Depreciation and amortization $ 10 Gain on sale of the Connected Care Business 32,211 Cash flows from investing activities: Net proceeds from sale of the Connected Care Business $ 46,401 Purchases of property and equipment, including internal-use software 76

Accounts Receivable, net

Accounts Receivable, net	3 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Accounts Receivable, net	Accounts Receivable, net Accounts receivable are included in the Consolidated Balance Sheets, net of the allowance for doubtful accounts. The allowance for doubtful accounts at March 31, 2021 and December 31, 2020 was $33 and $44, respectively.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities	3 Months Ended
	Mar. 31, 2021
Other Current Assets And Other Current Liabilities [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities Prepaid expenses and other current assets as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, Prepaid expenses $ 2,593 $ 2,268 Restricted cash 1,180 238 Other current assets 776 998 Prepaid expenses and other current assets $ 4,549 $ 3,504 Accrued and other current liabilities as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, Accrued payroll and related costs $ 8,235 $ 7,247 Operating lease liabilities 1,900 1,900 Other accrued and other current liabilities 5,697 4,828 Accrued and other current liabilities $ 15,832 $ 13,975
Accrued and Other Current Liabilities	Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities Prepaid expenses and other current assets as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, Prepaid expenses $ 2,593 $ 2,268 Restricted cash 1,180 238 Other current assets 776 998 Prepaid expenses and other current assets $ 4,549 $ 3,504 Accrued and other current liabilities as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, Accrued payroll and related costs $ 8,235 $ 7,247 Operating lease liabilities 1,900 1,900 Other accrued and other current liabilities 5,697 4,828 Accrued and other current liabilities $ 15,832 $ 13,975

Property, Plant and Equipment,

Property, Plant and Equipment, net	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, net	Property, Plant and Equipment, net Property, plant and equipment, net as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, Computer equipment and software $ 12,287 $ 12,332 Furniture and equipment 1,168 1,168 Leasehold improvements 4,286 4,282 Property, plant, and equipment, excluding internal-use software, gross 17,741 17,782 Less: Accumulated depreciation and amortization (13,225) (12,837) Property, plant and equipment, excluding internal-use software, net 4,516 4,945 Internal-use software 39,303 38,488 Construction in progress - Internal-use software 1,975 1,616 Less: Accumulated depreciation and amortization, internal-use software (32,935) (31,947) Internal-use software, net 8,343 8,157 Property, plant and equipment, net $ 12,859 $ 13,102 Depreciation expense from continuing operations was $1,411 for the three months ended March 31, 2021, of which $989 related to internal-use software costs. Depreciation and amortization expense from continuing operations was $2,008 for the three months ended March 31, 2020, of which $1,635 related to internal-use software costs. Amounts capitalized to internal-use software related to continuing operations for the three months ended March 31, 2021 and 2020 we re $890 and $1,210 , respectively.

Intangible Assets, net

Intangible Assets, net	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net The Company’s definite-lived intangible assets as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, Customer relationships $ 53,000 $ 53,000 Developed technologies 34,500 34,500 Trade name 3,300 3,300 Installed user base 1,400 1,400 Intangible assets, gross 92,200 92,200 Less: Accumulated amortization (46,463) (44,231) Intangible assets, net $ 45,737 $ 47,969 Amortization of definite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or the pattern in which economic benefits are consumed, if reliably determinable. The Company reviews its definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Amortization expense from continuing operations for the three months ended March 31, 2021 and 2020 was $2,232 and $2,010, respectively. At July 22, 2020, the Company recorded $5,200 of definite-lived intangible assets and accumulated amortization of $647 related to the assignment of OpenNMS (see Note 19). These intangible assets are amortized over a period of 4 to 6 years. The estimated future amortization expense over the next five years and thereafter for the intangible assets that exist as of March 31, 2021 is as follows: Amounts Remainder of 2021 $ 6,697 2022 8,930 2023 4,346 2024 4,283 2025 4,147 2026 3,467 Thereafter 13,867 Total future intangible amortization expense $ 45,737

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill Goodwill as of both March 31, 2021 and December 31, 2020 was $98,333 , net of goodwill allocated to the discontinued operation of $18,623 during 2020. The goodwill allocated to the discontinued operation was based on the fair value of the Connected Care Business as a percentage of the total fair value of the Connected Care Business and the Company that remains after the sales transaction (see Note 4). On July 22, 2020, the Company rec ognized $1,026 of good will related to the assignment of OpenNMS (see Note 19).

Investments

Investments	3 Months Ended
	Mar. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments Equity method investment Investment in NantOmics In 2015, the Company purchased a total of 169,074,539 Series A-2 units of NantOmics, LLC (“NantOmics”), a related party of the Company, for an aggregate purchase price of $250,774. The Series A-2 units do not have any voting rights and, at the time of purchase, represented approximately 14.28% of NantOmics’ issued and outstanding membership interests. NantOmics is majority owned by NantWorks and delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. At February 28, 2018, the Company transferred 9,088,362 of the Series A-2 units to NantOmics as consideration for the assignment of NantHealth Labs, Inc. (see Note 19). An additional 564,779 units were transferred by May 31, 2018. This reduced NantHealth's ownership of NantOmics to approximately 13.58%. The Company applies the equity method to account for its investment in NantOmics as the interest in the equity is similar to a partnership interest. Further, the Company has the ability to exert significant influence over the operating and financial policies of the entity since NantWorks controls both NantHealth and NantOmics. The difference between the carrying amount of the investment in NantOmics and the Company’s underlying equity in NantOmics’ net assets relate to both definite and indefinite-lived intangible assets. At the time of the purchase, the Company attributed $28,195 and $14,382 of these differences to NantOmics’ developed technologies and its reseller agreement with the Company, respectively, prior to the application of developed technology intangibles included in NantOmics net assets, and the remaining basis differences were attributed to goodwill. The Company amortizes the basis differences related to the definite-lived intangible assets over the assets’ estimated useful lives and records these amounts as a reduction in the carrying amount of its investment and an increase in its equity method loss. At June 30, 2020, the Company determined that an other-than-temporary-impairment of $28,227, the full remaining carrying value of the Company's investment in NantOmics, had occurred, through observation of Level 3 inputs predominantly attributed to (i) limited progress by NantOmics in completing revenue generating transactions for paid molecular analysis services for the research and pharmaceutical industries; (ii) limited progress in completing licensing transactions for proprietary molecular analysis technologies and/or intellectual property of NantOmics; and (iii) the Company's decision to shift future laboratory operations in-house related to the GPS Cancer and Omics Core products to better control the supply chain and CMS reimbursement process, which the Company expects to result in reduced fees to NantOmics. Pertaining to the Company's share of NantOmics' income or loss, amortization of basis differences, and other-than-temporary impairments, for the three months ended March 31, 2020, the Company recognized losses of $1,784. The Company did not recognize any income or losses during the three months ended March 31, 2021. The Company reports its share of NantOmics’ income or loss and the amortization of basis differences using a one quarter lag. As the Company's equity method investment in NantOmics was reduced to zero during the second quarter of 2020, the Company no longer applies the equity method as NantOmics continued to generate net losses. The Company used the following summarized financial information for NantOmics for the three months ended December 31, 2019, to record its equity method losses for the three months ended March 31, 2020: Revenues $ 223 Gross loss (1,163) Loss from operations (3,856) Net loss (1,360) Net loss attributable to NantOmics (1,329)

Convertible Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Convertible Notes	Convertible Notes In December 2016, the Company entered into the Purchase Agreement with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several initial purchasers named therein (collectively, the “Initial Purchasers”), to issue and sell $90,000 in aggregate principal amount of its 5.50% senior convertible notes due 2021 ("Convertible Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to non-U.S. persons pursuant to Regulation S under the Securities Act. In December 2016, the Company entered into a purchase agreement (the “Cambridge Purchase Agreement”) with Cambridge, an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Chairman and Chief Executive Officer, to issue and sell $10,000 in aggregate principal amount of the Convertible Notes in a private placement pursuant to an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act. In December 2016, pursuant to the exercise of the overallotment by the Initial Purchasers, the Company issued an additional $7,000 principal amount of the Convertible Notes. The total net proceeds from this offering were approximately $102,714, comprised of $9,917 from Cambridge and $92,797 from the Initial Purchasers, after deducting the Initial Purchasers’ discount and debt issuance costs of $4,286 in connection with the Convertible Notes offering. On December 21, 2016, the Company entered into an indenture, relating to the issuance of the Convertible Notes (the “Indenture”), by and between the Company and U.S. Bank National Association, as trustee (the “Trustee”). The interest rates are fixed at 5.50% per year, payable semi-annually on June 15th and December 15th of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2021, unless earlier repurchased by the Company or converted pursuant to their terms. In connection with the offering of the Convertible Notes, on December 15, 2016, the Company entered into a Second Amended and Restated Promissory Note which amended and restated the Amended and Restated Promissory Note, dated May 9, 2016, between the Company and Nant Capital, to, among other things, extend the maturity date of the promissory note to June 15, 2022 and to subordinate such promissory note in right of payment to the Convertible Notes (see Note 19). The initial conversion rate of the Convertible Notes is 82.3893 shares of common stock per $1 principal amount of Convertible Notes (which is equivalent to an initial conversion price of approximately $12.14 per share). Prior to the close of business on the business day immediately preceding September 15, 2021, the Convertible Notes will be convertible only under the following circumstances: (1) during any calendar quarter commencing after March 31, 2017 (and only during such calendar quarter), if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding calendar quarter, the last reported sale price of the Company’s common stock on such trading day is greater than or equal to 120% of the conversion price on such trading day; (2) during the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1 principal amount of the Convertible Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on such trading day; or (3) upon the occurrence of specified corporate transactions as described in the Indenture agreement. Upon conversion, the Convertible Notes will be settled in cash, shares of the Company’s common stock or any combination thereof at the Company’s option. Upon the occurrence of a fundamental change (as defined in the Indenture), holders may require the Company to purchase all or a portion of the Convertible Notes in principal amounts of $1 or an integral multiple thereof, for cash at a price equal to 100% of the principal amount of the Convertible Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date. The conversion rate will be subject to adjustment upon the occurrence of certain specified events. On or after the date that is one year after the last date of original issuance of the Convertible Notes, if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending within the five trading days immediately preceding a conversion date is greater than or equal to 120% of the conversion price on each applicable trading day, the Company will make an interest make-whole payment to a converting holder (other than a conversion in connection with a make-whole fundamental change in which the conversion rate is adjusted) equal to the sum of the present values of the scheduled payments of interest that would have been made on the Convertible Notes to be converted had such Convertible Notes remained outstanding from the conversion date through the earlier of (i) the date that is three years after the conversion date and (ii) the maturity date if the Convertible Notes had not been so converted. The present values of the remaining interest payments will be computed using a discount rate equal to 2.0%. The Company may pay any interest make-whole payment either in cash or in shares of its common stock, at the Company’s election as described in the Indenture. The Company accounted for convertible debt instruments that may be settled in cash upon conversion (including partial cash settlement) by recording the liability and equity components of the convertible debt separately. The liability component was computed based on the fair value of a similar liability that does not include the conversion option. The liability component included both the value of the embedded interest make-whole derivative and the carrying value of the Convertible Notes. The equity component was computed based on the total debt proceeds less the fair value of the liability component. The equity component was also recorded as debt discount and amortized as interest expense over the expected term of the Convertible Notes. The liability component of the Convertible Notes on the date of issuance was computed as $83,079, consisting of the value of the embedded interest make-whole derivative of $1,499 and the carrying value of the Convertible Notes of $81,580. Accordingly, the equity component on the date of issuance was $23,921. If the debt is considered current at the balance sheet date, the liability component of the convertible notes will be classified as current liabilities and presented in current portion of convertible notes debt and the equity component of the convertible debt will be considered a redeemable security and presented as redeemable equity on the Company's Consolidated Balance Sheet. Offering costs of $4,286 related to the issuance of the Convertible Notes were allocated to the liability and equity components in proportion to the allocation of the proceeds and accounted for as deferred financing offering costs and equity issuance costs, respectively. Approximately $972 of this amount was allocated to equity and the remaining $3,314 was capitalized as deferred financing offering costs. The Company adopted ASU No. 2020-06 on January 1, 2021 through a modified retrospective method of transition, which eliminated the separation model for convertible debt with a cash conversion feature, resulting in less noncash interest expense going forward (see Note 2). The cumulative effect of the adoption on January 1, 2021 was a decrease of $5,746 to unamortized debt discount and deferred financing offering costs. Th e debt discounts and deferred financing offering costs on the Convertible Notes are being amortized to interest expense over the contractual terms of the Convertible Notes, using the effective interest method at an effective interest rate of 6.78%. As of March 31, 2021, the remaining life of the Convertible Notes is approximately 9 months. On April 13, 2021, Highbridge and Cambridge each agreed to exchange $5,000 of its $36,945 and $10,000 in existing convertible notes, respectively, for shares of the Company’s common stock, par value $0.0001, pursuant to the Exchange Agreement (see Note 20). The following table summarizes how the issuance of the Convertible Notes is reflected in the Company's Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020. Related Party Others Total Balance as of March 31, 2021 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (37) (905) (942) Net carrying amount $ 9,963 $ 96,095 $ 106,058 Balance as of December 31, 2020 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (589) (6,422) (7,011) Net carrying amount $ 9,411 $ 90,578 $ 99,989 The following tables set forth the Company's interest expense recognized in the Company's Consolidated Statements of Operations: Three Months Ended March 31, 2021 Related Party Others Total Accrued coupon interest expense $ 137 $ 1,334 $ 1,471 Amortization of debt discounts 8 76 84 Amortization of deferred financing offering costs 5 234 239 Total convertible notes interest expense $ 150 $ 1,644 $ 1,794 Three Months Ended March 31, 2020 Related Party Others Total Accrued coupon interest expense $ 137 $ 1,334 $ 1,471 Amortization of debt discounts 127 1,238 1,365 Amortization of deferred financing offering costs 3 174 177 Total convertible notes interest expense $ 267 $ 2,746 $ 3,013

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, 2021 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Liabilities Bookings Commitment $ 35,114 $ — $ — $ 35,114 December 31, 2020 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Liabilities Bookings Commitment $ 32,651 $ — $ — $ 32,651 Interest make-whole derivative 4 — — 4 The Company’s intangible assets and goodwill are initially measured at fair value and any subsequent adjustment to the initial fair value occurs only if an impairment charge is recognized. Level 3 Inputs Bookings Commitment On August 3, 2017, the Company entered into an asset purchase agreement (the “APA”) with Allscripts Healthcare Solutions, Inc. (“Allscripts”), pursuant to which the Company agreed to sell to Allscripts substantially all of the assets of the Company’s provider/patient engagement solutions business, including the Company’s FusionFX solution and components of its NantOS software connectivity solutions (the “Business”). On August 25, 2017, the Company and Allscripts completed the sale of the Business (the "Disposition") pursuant to the APA. Concurrent with the closing of the Disposition and as contemplated by the APA, (a) the Company and Allscripts modified the amended and restated mutual license and reseller agreement dated June 26, 2015, which was further amended on December 30, 2017, such that, among other things, the Company committed to deliver a minimum of $95,000 of total bookings over a ten-year period (“Bookings Commitment”) from referral transactions and sales of certain Allscripts products; (b) the Company and Allscripts each licensed certain intellectual property to the other party pursuant to a cross license agreement; (c) the Company agreed to provide certain transition services to Allscripts pursuant to a transition services agreement; and (d) the C ompany licensed certain software and agreed to sell certain hardware to Allscripts pursuant to a software license and supply agreement. The Company also agreed that Allscripts shall receive at least $500 per year in payments from bookings (the “Annual Minimum Commitment”). If the total payments received by Allscripts from bookings during such period are less than the Annual Minimum Commitment, the Company shall pay to Allscripts the difference between the Annual Minimum Commitment and the total amount received by Allscripts from bookings during such period. A s of both March 31, 2021 and December 31, 2020, the accrued Annual Minimum Commitment was $1,200. In the event of a Bookings Commitment shortfall at the end of the ten-year period, the Company may be obligated to pay 70% of the shortfall, subject to certain credits. The Company will earn 30% commission from Allscripts on each software referral transaction that results in a booking with Allscripts. The Company accounts for the Bookings Commitment at its estimated fair value over the life of the agreement. The Company values the Bookings Commitment, assumed upon the disposal of the provider/patient engagement solutions business, using a Monte Carlo Simulation model to calculate average payments due under the Bookings Commitment, based on management's estimate of its performance in securing bookings and resulting annual payments, discounted at the cost of debt based on a yield curve. The cost of debt used for discounting was between 8% and 10% at March 31, 2021 and between 10% and 11% at December 31, 2020. The change in fair value is recorded within other income (expense), net in the Company's Consolidated Statements of Operations. The fair value of the Bookings Commitment is dependent on management's estimate of the probability of success on individual opportunities and the cost of debt applied in discounting the liability. The higher the probability of success on each opportunity, the lower the fair value of the Bookings Commitment liability. The lower the cost of debt applied, the higher the value of the liability. Management believes the assumptions used on projected financial information is reasonable, but those assumptions require judgment and are forward looking in nature. However, actual results may differ materially from those projections. The fair value of the Bookings Commitment is most sensitive to management's estimate of the discount rate applied to present value the liability. If the discount rate applied was 2% lower at March 31, 2021, the fair value of the liability would increase by $4,511. Convertible Note derivative liability In December 2016, the Company issued $107,000 in aggregate principal amount of Convertible Notes due December 15, 2021, of which $10,000 issued to a related party (see Note 11). The Convertible Notes include an interest make-whole feature whereby if a noteholder converts any of the Convertible Notes one year after the last date of original issuance of the Convertible Notes, they are entitled, in addition to the other consideration payable or deliverable in connection with such conversion, to an interest make-whole payment equal to the sum of the present values of the scheduled payments, computed using a discount rate equal to 2.0%, of interest that would have been made on the Convertible Notes to be converted had such Convertible Notes remained outstanding from the conversion date through the earlier of (i) the date that is three years after the conversion date and (ii) the maturity date if the Convertible Notes had not been so converted. The Company may pay any interest make-whole payment either in cash or in shares of its common stock, at the Company’s election as described in the Indenture. The Company has determined that this feature is an embedded derivative. The fair value of the derivative liability includes the estimated volatility and risk-free rate. The higher/lower the estimated volatility, the higher/lower the value of the liability. The higher/lower the risk-free interest rate, the higher/lower the value of the liability. The fair market value for level 3 securities may be highly sensitive to the use of unobservable inputs and subjective assumptions. Generally, changes in significant unobservable inputs may result in significantly lower or higher fair value measurements. The following tables set forth a summary of changes in the fair value of Level 3 liabilities for the three months ended March 31, 2021: December 31, 2020 Transfers in (out) Change in fair value recognized in earnings March 31, 2021 Liabilities Interest make-whole derivative - related party and others $ 4 $ — $ (4) $ — Bookings Commitment 32,651 — 2,463 35,114 $ 32,655 $ — $ 2,459 $ 35,114 Fair Value of Convertible Notes held at amortized cost As of March 31, 2021 and December 31, 2020, the fair value and carrying value of the Company's Convertible Notes were: Fair value Carrying value Face value 5.5% convertible senior notes due December 15, 2021: Balance as of March 31, 2021 Related party $ 9,896 $ 9,963 $ 10,000 Others 95,991 96,095 97,000 $ 105,887 $ 106,058 $ 107,000 Balance as of December 31, 2020 Related party $ 9,553 $ 9,411 $ 10,000 Others 92,660 90,578 97,000 $ 102,213 $ 99,989 $ 107,000 The fair value shown above represents the fair value of the debt instrument, inclusive of both the debt and equity components, but excluding the derivative liability. The carrying value represents only the carrying value of the debt component. The fair value of the Convertible Notes was determined by using unobservable inputs that are supported by minimal non-active market activity and that are significant to determining the fair value of the debt instrument. The fair value is level 3 in the fair value hierarchy.

Leases

Leases	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	Leases Future minimum lease payments under the Company's operating leases at March 31, 2021 were: Maturity Analysis Amounts Remainder of 2021 $ 2,147 2022 2,683 2023 2,691 2024 2,537 2025 684 2026 613 Thereafter 1,087 Total future minimum lease payments 12,442 Less: imputed interest (2,819) Total $ 9,623 As reported in the Consolidated Balance Sheet Accrued and other current liabilities $ 1,900 Operating lease liabilities 7,723 $ 9,623

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company's principal commitments consist of obligations under its outstanding debt obligations, noncancelable leases for its office space, data centers and certain equipment and vendor contracts to provide research services, and purchase obligations under license agreements and reseller agreements. Related Party Promissory Note On January 4, 2016, the Company executed a $112,666 demand promissory note in favor of Nant Capital to fund the acquisition of NaviNet ( see Note 19). On May 9, 2016 and December 15, 2016, the promissory note with Nant Capital was amended to provide that all outstanding principal and accrued interest is due and payable on June 15, 2022, and not on demand and the Company subordinated the promissory note in right of payment to the Convertible Notes (see Note 11). On April 27, 2021, in connection with the issuance of the 2026 Notes, the Company entered into a Third Amended and Restated Promissory Note (see Note 20). Indenture Obligations Under Convertible Notes On December 21, 2016, the Company entered into the Indenture relating to the issuance of the $107,000 Convertible Notes, by and between the Company and U.S. Bank National Association the Trustee. The interest rates are fixed at 5.50% per year, payable semi-annually on June 15th and December 15th of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2021, unless earlier repurchased by the Company or converted pursuant to their terms (see Note 11). On April 27, 2021, the Company entered into the 2021 Indenture by and among the Company, the Guarantor and the Trustee pursuant to which NantHealth issued the 2026 Notes (see Note 20). Unconditional Purchase Obligations In 2020, NantWorks entered into agreements with various vendors related to an enterprise resource planning (“ERP”) implementation project on behalf of its subsidiaries, including NantHealth. NantWorks bills the Company for its portion of these expenses through the Shared Services Agreement (see Note 19). As of March 31, 2021, the Company’s estimated unconditional purchase obligations total approximately $500 for the remainder of 2021, $600 in 2022, and $100 in 2023. During the three months ended March 31, 2021, the Company made payments of approximately $111 for the amounts purchased related to the unconditional purchase obligations for the ERP implementation project. Regulatory Matter The Company is subject to regulatory oversight by the U.S. Food and Drug Administration and other regulatory authorities with respect to the development, manufacturing, and sale of some of the solutions. In addition, the Company is subject to the Health Insurance Portability and Accountability Act (“HIPAA”), the Health Information Technology for Economic and Clinical Health Act and related patient confidentiality laws and regulations with respect to patient information. The Company reviews the applicable laws and regulations regarding effects of such laws and regulations on its operations on an on-going basis and modifies operations as appropriate. The Company believes it is in substantial compliance with all applicable laws and regulations. Failure to comply with regulatory requirements could have a significant adverse effect on the Company’s business and operations. Legal Matters The Company is, from time to time, subject to claims and litigation that arise in the ordinary course of its business. Except as discussed below, in the opinion of management, the ultimate outcome of proceedings of which management is aware, even if adverse to the Company, would not have a material adverse effect on the Company’s consolidated financial condition or results of operations. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Securities and Derivative Litigation In March 2017, a number of putative class action securities complaints were filed in U.S. District Court for the Central District of California, naming as defendants the Company and certain of our current or former executive officers and directors. These complaints have been consolidated with the lead case captioned Deora v. NantHealth, Inc., 2:17-cv-01825 ("Deora"). In June 2017, the lead plaintiffs filed an amended consolidated complaint, which generally alleges that defendants violated federal securities laws by making material misrepresentations in NantHealth’s IPO registration statement and in subsequent public statements. In particular, the complaint refers to various third-party articles in alleging that defendants misrepresented NantHealth’s business with the University of Utah, donations to the university by non-profit entities associated with the Company's founder Dr. Patrick Soon-Shiong, and orders for GPS Cancer. The lead plaintiffs seek unspecified damages and other relief on behalf of putative classes of persons who purchased or acquired NantHealth securities in the IPO or on the open market from June 1, 2016 through May 1, 2017. In March 2018, the Court largely denied Defendants’ motion to dismiss the consolidated amended complaint. On July 30, 2019, the Court certified the case as a class action. On October 23, 2019, the parties notified the Court that they had reached a settlement in principle to resolve the action on a class wide basis in the amount of $16,500, which was included in accrued and other current liabilities in the Consolidated Balance Sheet at December 31, 2019. The Court granted preliminary approval of the settlement on January 31, 2020. A hearing for final approval of the settlement was scheduled for June 15, 2020, but on June 5, 2020, the Court decided to take the final approval motion on submission, and on July 17, 2020, the Court directed Plaintiff’s counsel to submit evidence substantiating all costs incurred. The $16,500 settlement was paid into a settlement fund prior to the payment deadline of March 2, 2020. The majority of the settlement amount was funded by the Company’s insurance carriers, and a portion was by the Company. On September 10, 2020, the Court entered an order granting final approval of the settlement, and the order and settlement are now final. In May 2017, a putative class action complaint was filed in California Superior Court, Los Angeles County, asserting claims for violations of the Securities Act based on allegations similar to those in Deora. That case is captioned Bucks County Employees Retirement Fund v. NantHealth, Inc., BC 662330. At a case management conference on December 3, 2019, the parties informed the court of the pending settlement of the federal class action in the Deora action. During a status conference on February 4, 2021, the Court scheduled a further status conference for April 7, 2021 and stated that if Plaintiff did not voluntarily dismiss the action, the Court would entertain a motion to dismiss in light of the finalization of the Deora settlement. Plaintiff filed an unopposed request for voluntarily dismissal on March 15, 2021. On March 22, 2021, the court issued an order granting plaintiff’s request and dismissing the action with prejudice. In April 2018, two putative shareholder derivative actions, captioned Engleman v. Soon-Shiong, Case No. 2018-0282-AGB, and Petersen v. Soon-Shiong, Case No. 2018-0302-AGB were filed in the Delaware Court of Chancery. The plaintiff in the Engleman action previously filed a similar complaint in California Superior Court, Los Angeles County, which was dismissed based on a provision in the Company’s charter requiring derivative actions to be brought in Delaware. The Engleman and Petersen complaints contain allegations similar to those in the Deora action but asserted causes of action on behalf of NantHealth against various of the Company’s current or former executive officers and directors for alleged breaches of fiduciary duty, abuse of control, gross mismanagement, waste of corporate assets, and unjust enrichment. The Company is named solely as a nominal defendant. In July 2018, the court issued an order consolidating the Engleman and Petersen actions as In re NantHealth, Inc. Stockholder Litigation, Lead C.A. No. 2018-0302, appointing Petersen as lead plaintiff, and designating the Petersen complaint as the operative complaint. On September 20, 2018, the defendants moved to dismiss the complaint. In October 2018, in response to the motion to dismiss, Petersen filed an amended complaint. In November 2018, the defendants moved to dismiss the amended complaint, which asserts claims for breach of fiduciary duty, waste of corporate assets (which Petersen subsequently withdrew), and unjust enrichment. On January 14, 2020, the court issued an order granting in part and denying in part the defendants’ motion to dismiss. The court dismissed all claims except one claim against Dr. Patrick Soon-Shiong for breach of fiduciary duty. Dr. Soon-Shiong and the Company filed answers to the amended complaint on March 30, 2020. Discovery commenced and the action remains pending. In April 2018, a putative shareholder derivative action captioned Shen v. Soon-Shiong was filed in U.S. District Court for the District of Delaware. In November 2018, a putative shareholder derivative action captioned Manuel v. Soon-Shiong was filed in the U.S. District Court for the District of Delaware. The complaints contain allegations similar to those in the Deora action but also asserted causes of action on behalf of NantHealth against various of the Company’s current or former executive officers and directors for alleged breaches of fiduciary duty and unjust enrichment, as well as alleged violations of the federal securities laws based on alleged misstatements or omissions in the Company’s 2017 proxy statement. The Company is named solely as a nominal defendant. On January 15, 2019, the Shen and Manuel actions were consolidated in a case captioned In re NantHealth, Inc. Derivative Litigation. The parties agreed to stay the consolidated case pending a decision on defendants’ motion to dismiss in the derivative action in the Delaware Court of Chancery. The stay was lifted after the Delaware Court of Chancery's January 14, 2020 decision granting in part and denying in part the motion to dismiss. On October 5, 2020, an amended consolidated complaint was filed which brings claims only against Dr. Soon-Shiong for alleged violations of the federal securities laws and breach of fiduciary duty based on alleged misstatement or omissions in the Company’s 2017 and 2018 proxy statements and other public filings. On December 4, 2020, defendant moved to dismiss the amended complaint. On February 2, 2021, plaintiffs filed an answering brief in opposition to defendant’s motion to dismiss. On March 18, 2021, defendant filed a reply brief in further support of his motion to dismiss the amended complaint. Insurance Recoveries The Company has reflected its right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with the Company’s third-party insurers and receipt is deemed probable. This includes instances where the Company’s third-party insurers have agreed to pay, on the Company’s behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. The amount of such receivable related to the securities litigation recorded at March 31, 2021 and December 31, 2020 was $98 and $253, respectively, and is included in prepaid expenses and other current assets in the Consolidated Balance Sheets.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes for the three months ended March 31, 2021 and 2020 from continuing operations was a benefit of $8 and a provision of $93, respectively. The (benefit from) provision for income taxes for the three months ended March 31, 2021 and 2020 from continuing operations included an income tax (benefit) provision for the consolidated group based on an estimated annual effective tax rate. The effective tax rates for the three months ended March 31, 2021 and 2020 from continuing operations were a benefit of 0.05% and a provision of 1.05%, respectively. The effective tax rates for the three months ended March 31, 2021 and 2020 differed from the U.S. federal statutory rates of 21% primarily as a result of a valuation allowance on the Company's deferred tax assets.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Amended Certificate of Incorporation In accordance with the Company’s amended and restated certificate of incorporation, which was filed immediately following the closing of its IPO, the Company is authorized to issue 750,000,000 shares of common stock, with a par value of $0.0001 per share, and 20,000,000 shares of undesignated preferred stock, with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share held on all matters submitted to a vote of its stockholders. Holders of the Company’s common stock have no cumulative voting rights. Further, as of March 31, 2021 and December 31, 2020, holders of the Company’s common stock have no preemptive, conversion, redemption or subscription rights and there are no sinking fund provisions applicable to the Company’s common stock. Upon liquidation, dissolution or winding-up of the Company, holders of the Company’s common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of the Company’s common stock are entitled to receive dividends, if any, as may be declared from time to time by the Company’s board of directors. As of March 31, 2021, and December 31, 2020, there were no outstanding shares of preferred stock.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table reflects the components of stock-based compensation expense recognized in the Company's Consolidated Statements of Operations: Three Months Ended 2021 2020 Phantom units: Cost of revenue $ — $ 16 Selling, general and administrative — 9 Research and development — 17 Total phantom units stock-based compensation expense — 42 Stock options: Cost of revenue 42 15 Selling, general and administrative 698 237 Research and development 98 24 Total stock options stock-based compensation expense 838 276 Restricted stock units: Cost of revenue — 7 Selling, general and administrative 49 389 Research and development — 18 Total restricted stock units stock-based compensation expense 49 414 Discontinued operations — (79) Total stock-based compensation expense 887 653 Amount capitalized to internal-use software 25 19 Total stock-based compensation cost $ 912 $ 672 2016 Equity Incentive Plan Stock Options The following table summarizes the activity related to stock options during the three months ended March 31, 2021: Number of Shares Weighted-Average Exercise Price Stock options outstanding - December 31, 2020 10,025,124 $ 2.19 Exercised (103,900) $ 0.55 Forfeited (242,500) $ 3.05 Stock options outstanding - March 31, 2021 9,678,724 $ 2.18 Stock options exercisable - March 31, 2021 2,707,474 $ 0.57 As of March 31, 2021, the Company had $10,111 of unrecognized stock-based compensation expense related to stock options. This cost is expected to be recognized over a weighted-average period of 2.5 years. The Company settles all exercised stock options by issuing shares of the Company's common stock without netting down the portion related to payroll withholding tax obligations. Restricted Stock Units The following table summarizes the activity related to the unvested restricted stock units during the three months ended March 31, 2021: Number of Units Weighted-Average Grant Date Fair Value Unvested restricted stock units outstanding - December 31, 2020 253,308 $ 1.64 Vested (59,853) $ 1.81 Unvested restricted stock units outstanding - March 31, 2021 193,455 $ 1.59 As of March 31, 2021, the Company had $227 of unrecognized stock-based compensation expense related to restricted stock units. This cost is expected to be recognized over a weighted-average period of 0.5 years. During the three months ended March 31, 2021, the Company issued 59,853 shares of common stock to participants of the 2016 Plan based in the United States.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net (Loss) Income Per Share The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net (loss) income per share of common stock attributable to NantHealth for the three months ended March 31, 2021 and 2020: Three Months Ended 2021 2020 Common Stock Common Stock Net (loss) income per share numerator: Net loss from continuing operations $ (15,503) $ (8,940) Net loss attributable to noncontrolling interests (91) — Net loss from continuing operations attributable to NantHealth (15,412) (8,940) Income from discontinued operations attributable to NantHealth 4 32,005 Net (loss) income attributable to NantHealth for basic and diluted net loss per share $ (15,408) $ 23,065 Weighted-average shares for basic and diluted net (loss) income per share 111,319,061 110,619,780 Basic and diluted net (loss) income per share attributable to NantHealth: Continuing operations - common stock $ (0.14) $ (0.08) Discontinued operations - common stock $ — $ 0.29 Total net (loss) income per share - common stock $ (0.14) $ 0.21 The following number of potential common shares at the end of each period were excluded from the calculation of diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive for the periods presented: March 31, 2021 2020 Unvested phantom units — 115,108 Unvested restricted stock units 193,455 874,019 Unexercised stock options 9,678,724 5,545,724 Convertible notes 8,815,655 8,815,655

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions NantWorks Shared Services Agreement In October 2012, the Company entered into a shared services agreement with NantWorks that provides for ongoing services from NantWorks in areas such as public relations, information technology and cloud services, human resources and administration management, finance and risk management, environmental health and safety, sales and marketing services, facilities, procurement and travel, and corporate development and strategy (the "Shared Services Agreement"). The Company is billed quarterly for such services at cost, without mark-up or profit for NantWorks, but including reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the associates providing the services. NantHealth also bills NantWorks and affiliates for services such as information technology and cloud services, finance and risk management, and facilities management, on the same basis. During the three months ended March 31, 2021, the Company recognized $106 of expenses in selling, general and administrative expenses for services provided to the Company by NantWorks and affiliates, net of services provided to NantWorks and affiliates. During the three months ended March 31, 2020, the Company incurred $486 of expenses recognized in selling, general and administrative expenses for services provided to the Company by NantWorks and affiliates, net of services provided to NantWorks and affiliates. Related Party Receivables and Payables As of March 31, 2021 and December 31, 2020, the Company had related party receivables of $1,848 and $1,854, respectively, primarily consisting of a receivable from Ziosoft KK of $1,477 in both periods, which was related to the sale of Qi Imaging. As of March 31, 2021 and December 31, 2020, respectively, the Company had related party payables and related party liabilities of $36,952 and $35,329, respectively, which primarily relate to amounts owed to NantWorks pursuant to the Shared Services Agreement, amounts owed to NantOmics under the Second Amended Reseller Agreement (defined below), and interest payable. The balance of the related party receivables and payables represent amounts paid by affiliates on behalf of the Company or vice versa. Assignment of The OpenNMS Group, Inc. On July 22, 2020, the Company entered into an assignment agreement (the “Assignment Agreement”) with Cambridge to acquire approximately 91% of The OpenNMS Group, Inc. for $5,577 in cash. Contemporaneously with the closing of the Assignment Agreement, OpenNMS issued call options to the Company consisting of, when exercised, cash payment of $278 and issuance of 56,769 shares of the Company's common stock in exchange for the 9% of the shares of OpenNMS common stock held by the remaining shareholders. These call options expired unexercised on September 30, 2020. As the Company and Cambridge are controlled by the Company's Chairman and CEO, the acquisition was treated as a transaction between entities under common control. The Company recognized the assets and liabilities transferred under the Assignment Agreement at their carrying amounts on July 22, 2020 based on Cambridge's historical cost, including the effects of purchase accounting from the November 1, 2019 acquisition of OpenNMS by Cambridge. The transaction did not cause a material change in the reporting entity, and the Company has not retrospectively adjusted its previously issued financial statements. The intangible assets acquired are amortized over the weighted-average useful life of 5.9 years. These definite-lived intangible assets include developed technology of $2,500 (6-year useful life), installed user base of $1,400 (6-year useful life), customer relationship of $1,000 (6-year useful life), and trade name of $300 (4-year useful life). Amounts Total cash consideration $ 5,577 Assets and liabilities of OpenNMS at assignment: Cash and cash equivalents 102 Goodwill 1,026 Intangible asset, net 4,553 Other assets 1,097 Other liabilities assumed (1,227) Net assets acquired at assignment 5,551 Noncontrolling interests (503) Recorded as distribution from additional paid-in capital $ 529 Amended Reseller Agreement On June 19, 2015, the Company entered into a five and a half year exclusive Reseller Agreement with NantOmics for sequencing and bioinformatics services (the "Original Reseller Agreement"). NantOmics is a majority owned subsidiary of NantWorks and is controlled by the Company's Chairman and CEO. On May 9, 2016, the Company and NantOmics executed an Amended and Restated Reseller Agreement (the “Amended Reseller Agreement”), pursuant to which the Company received the worldwide, exclusive right to resell NantOmics’ quantitative proteomic analysis services, as well as related consulting and other professional services, to institutional customers (including insurers and self-insured healthcare providers) throughout the world. The Company retained its existing rights to resell NantOmics’ molecular analysis and bioinformatics services. Under the Amended Reseller Agreement, the Company is responsible for various aspects of delivering its sequencing and molecular analysis solutions, including patient engagement and communications with providers such as providing interpretations of the reports delivered to the physicians and resolving any disputes, ensuring customer satisfaction, and managing billing and collections. On September 20, 2016, the Company and NantOmics further amended the Amended Reseller Agreement (the "Second Amended Reseller Agreement"). The Second Amended Reseller Agreement permits the Company to use vendors other than NantOmics to provide any or all of the services that are currently being provided by NantOmics and clarifies that the Company is responsible for order fulfillment and branding. The Second Amended Reseller Agreement grants to the Company the right to renew the agreement (with exclusivity) for up to three renewal terms, each lasting three years, if the Company achieves projected volume thresholds, as follows: (i) the first renewal option can be exercised if the Company completes at least 300,000 tests between June 19, 2015 and June 30, 2020; (ii) the second renewal option can be exercised if the Company completes at least 570,000 tests between July 1, 2020 and June 30, 2023; and (iii) the third renewal option can be exercised if the Company completes at least 760,000 tests between July 1, 2023 and June 30, 2026. If the Company does not meet the applicable volume threshold during the initial term or the first or second exclusive renewal terms, the Company can renew for a single additional three The Company agreed to pay NantOmics noncancelable annual minimum fees of $2,000 per year for each of the calendar years from 2016 through 2020 and, subject to the Company exercising at least one of its renewal options described above. The Company was also required to pay annual minimum fees to from 2021 through 2029. These annual minimum fees are no longer applicable with the execution of Amendment No. 3 to the Second Amended Reseller Agreement. On December 18, 2017, the Company and NantOmics executed Amendment No. 1 to the Second Amended Reseller Agreement. The Second Amended Reseller Agreement was amended to allow fee adjustments with respect to services completed by NantOmics between the amendment effective date of October 1, 2017 to June 30, 2018. On April 23, 2019, the Company and NantOmics executed Amendment No. 2 to the Second Amended Reseller Agreement. The Second Amended Reseller Agreement was amended to set a fixed fee with respect to services completed by NantOmics between the amendment effective date and the end of the Initial Term, December 31, 2020. On December 31, 2020, the Company and NantOmics executed Amendment No. 3 to the Second Amended Reseller Agreement to automatically renew at the end of December 2020 for a non-exclusive renewal term and to waive the annual minimum fee for the 2020 calendar year and calendar years 2021 through 2023. As of March 31, 2021 and December 31, 2020, the Company had $0 and $3, respectively, of outstanding related party payables under the Second Amended Reseller Agreement. During the three months ended March 31, 2021, direct costs of $0 were recorded as cost of revenue related to the Second Amended Reseller Agreement. During the three months ended March 31, 2020, direct costs of $36 were recorded as cost of revenue related to the Second Amended Reseller Agreement. Cambridge Purchase Agreement On December 15, 2016, the Company entered into the Cambridge Purchase Agreement with Cambridge, an entity affiliated with the Company's Chairman and CEO, Dr. Patrick Soon-Shiong, to issue and sell $10,000 in aggregate principal amount of the Convertible Notes in a private placement pursuant to an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act. The Cambridge Purchase Agreement includes customary representations, warranties and covenants by the Company and customary closing conditions (see Note 11). The accrued and unpaid interest on the Convertible Notes held by Cambridge was $162 an d $24 at March 31, 2021 and December 31, 2020, respectively, as part of current related party payables, net in the Consolidated Balance Sheets. On April 13, 2021, Cambridge agreed to exchange $5,000 of its $10,000 in Convertible Notes due 2021 for shares of the Company’s common stock, par value $0.0001 (see Note 20). Liquid Tumor Profiling Services Agreements In March 2018, NantHealth Labs, a wholly-owned subsidiary of the Company, and NantKwest, Inc. ("NantKwest"), an affiliate, entered into agreements whereby NantHealth Labs is providing liquid tumor profiling services to NantKwest for clinical trials, on an annual, stand-ready, basis from the date of the first test of each participant, with revenues recognized ratably over time for the period of the stand-ready obligation. In June 2018, NantHealth Labs entered into similar agreements to provide liquid tumor profiling services to Altor BioScience ("Altor"), NantCel l, Inc. ("NantCell"), and NantBioScience, Inc. ("NantBio"), all affiliates of the Company. During both the three months ended March 31, 2021 and 2020, the Company did not record any revenue under these agreements. As of both March 31, 2021 and December 31, 2020, the Company had accounts receivable from related parties due to these agreements of $110. Related Party Promissory Notes On January 4, 2016, the Company executed a $112,666 demand promissory note in favor of Nant Capital to fund the acquisition of NaviNet. The note bears interest at a per annum rate of 5.0%, compounded annually and computed on the basis of the actual number of days elapsed and a year of 365 or 366 days, as the case may be. The unpaid principal and any accrued and unpaid interest on the note were originally due and payable on demand in either (i) cash, (ii) shares of the Company's common stock based on per share price of $18.6126, (iii) Series A-2 units of NantOmics based on a per unit price of $1.484 to the extent such equity is owned by the Company or (iv) any combination of the foregoing, all at the option of Nant Capital. Subject to the preceding sentence, the Company may prepay the outstanding amount at any time, either in whole or in part, without premium or penalty and without the prior consent of Nant Capital. On May 9, 2016, the promissory note with Nant Capital was amended to provide that all outstanding principal and accrued interest is due and payable on June 30, 2021, and not on demand. On December 15, 2016, in connection with the offering of the Convertible Notes, the Company entered into a Second Amended and Restated Promissory Note which amends and restates the Amended and Restated Promissory Note, dated May 9, 2016, between the Company and Nant Capital, to, among other things, extend the maturity date of the promissory note to June 15, 2022 and to subordinate the promissory note in right of payment to the Convertible Notes (see Note 11). No other terms of the promissory note were changed. As of March 31, 2021 and December 31, 2020, the total principal and interest outstanding on the promissory note amounted to $145,526 and $143,756, respectively. The accrued and unpaid interest on the promissory note as of March 31, 2021 and December 31, 2020 was $32,860 and $31,090, respectively, included as part of noncurrent related party liabilities in the Consolidated Balance Sheets. The Company can request additional advances subject to Nant Capital approval. There are no other stated restrictions or maximum commitment for advances. Nant Capital has the option, but not the obligation, to require the Company to repay any such amount in cash, Series A-2 units of NantOmics (based on a per unit price of $1.484) held by the Company, shares of the Company's common stock based on a per share price of $18.6126 (if such equity exists at the time of repayment), or any combination of the foregoing at the sole discretion of Nant Capital. On April 27, 2021, in connection with the issuance of the 2026 Notes, the Company entered into a Third Amended and Restated Promissory Note (see Note 20). On January 22, 2016, the Company executed a demand promissory note in favor of NantOmics. The principal amount of the initial advance totaled $20,000. On March 8, 2016, NantOmics made a second advance to the Company for $20,000. The note bears interest at a per annum rate of 5.0% and is compounded annually. In May and June of 2016, the Company executed amendments to the demand promissory note with NantOmics, which provide that all unpaid principal of each advance owed to NantOmics and any accrued and unpaid interest would convert automatically into shares of the Company’s common stock after pricing of the Company’s IPO and immediately after conversion of the Company from a limited liability company to a corporation. On June 1, 2016, approximately $40,590 of principal and accrued interest under the promissory note with NantOmics was converted into 2,899,297 shares of the Company’s common stock in connection with the IPO. The amendments also provided a maturity date for the promissory note of June 30, 2021. The Company can request additional advances subject to NantOmics approval. There are no other stated restrictions or maximum commitment for advances. As of March 31, 2021, there was no outstanding balance on the promissory note. On April 26, 2021, in connection with the issuance of the 2026 Notes, the Company and NantOmics entered into an agreement to terminate the promissory note (see Note 20). On August 8, 2018, the Company executed a promissory note in favor of Nant Capital, with a maturity date of June 15, 2022. On December 31, 2020, the Company and Nant Capital executed an agreement to amend and restate the original promissory note allowing the Company to request advances up a maximum commitment of $125,000 that bears interest at a per annum rate of 5.50%, extended the maturity date to December 31, 2023, and created an option for the securitization of the debt under the promissory note upon full repayment of the Convertible Notes. Interest payments on outstanding amounts are due on December 15th of each calendar year. The promissory note is subordinated to the Convertible Notes (see Note 11). The promissory note includes customary negative covenants. No advances have currently been made under the note. At March 31, 2021, the Company was in compliance with the covenants. On April 27, 2021, in connection with the issuance of the 2026 Notes, the Company and Nant Capital entered into a Second Amended and Restated Promissory Note (see Note 20). Related Party Share-based Payments On December 21, 2020, ImmunityBio, Inc. (formerly known as NantKwest, Inc.) ("ImmunityBio"), NantCell, and Nectarine Merger Sub, Inc., a wholly owned subsidiary of ImmunityBio, entered into an Agreement and Plan of Merger, which was completed on March 9, 2021 (the "Merger"). The newly merged entity is majority owned by entities controlled by Dr. Patrick Soon-Shiong, Chairman and Chief Executive Officer of the Company. On March 4, 2021, prior to the Merger, NantCell awarded restricted stock units to its employees and nonemployees of the company and its affiliates, including certain NantHealth employees, which vests over defined service periods, subject to completion of a liquidity event. At the effective time of the Merger on March 9, 2021, the performance condition was met and each share of common stock of NantCell that was issued and outstanding immediately prior to the Merger was automatically converted into the right to receive as consideration newly issued common shares of ImmunityBio. The Company accounts for these awards as compensation cost at its estimated fair value over the vesting period with a corresponding credit to equity to reflect a capital contribution from, or on behalf of, the common controlling entity, to the extent that those services provided by its employees associated with these awards benefit NantHealth. The fair value is dependent on management's estimate of the benefit to NantHealth. The higher the estimate of benefit to the Company, the higher the fair value of compensation cost. The compensation cost attributed to NantHealth associated with these awards was not material for the three months ended March 31, 2021.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Equitization and Exchange Agreement On April 13, 2021, NantHealth entered into a transaction with Highbridge Capital Management, LLC and one of its affiliates (“Highbridge”) to exchange $5,000 of its $36,945 in existing convertible notes and with Cambridge to exchange $5,000 of its $10,000 in existing convertible notes for shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), pursuant to an exchange agreement dated as of April 13, 2021 (the “Exchange Agreement”). Note Purchase Agreement On April 13, 2021, NantHealth entered into a note purchase agreement (the “Note Purchase Agreement”) with NaviNet (the “Guarantor”) and certain buyers, including Highbridge and Nant Capital, to issue and sell $137,500 in aggregate principal amount of its 4.50% convertible senior notes due 2026 (the “2026 Notes”) in a private placement pursuant to an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act. The Note Purchase Agreement includes customary representations, warranties and covenants by the Company and customary closing conditions. Under the terms of the Note Purchase Agreement, the Company has agreed to indemnify the buyers against certain liabilities. The 2026 Notes were issued on April 27, 2021. The total net proceeds from this offering were approximately $137,382, comprised of $62,500 from Nant Capital and $74,882 from Highbridge, after deducting Highbridge’s debt issuance costs of $118 in connection with the 2026 Notes offering. Termination of NantOmics Promissory Note On April 26, 2021, in connection with the issuance of the 2026 Notes, the Company entered into an agreement with NantOmics to terminated its demand promissory note in favor of NantOmics, dated January 22, 2016, as amended during May and June of 2016. Amended and Restated Promissory Notes On April 27, 2021, in connection with the issuance of the 2026 Notes, the Company entered into a Third Amended and Restated Promissory Note which amends and restates its promissory note, dated January 4, 2016, as amended on May 9, 2016, and on December 15, 2016, between the Company and Nant Capital, to, among other things, extend the maturity date of the promissory note to October 1, 2026 and to subordinate the promissory note in right of payment to the 2026 Notes. On April 27, 2021, in connection with the issuance of the 2026 Notes, the Company entered into a Second Amended and Restated Promissory Note which amends and restates its promissory note, dated August 8, 2018, as amended on December 31, 2020, between the Company and Nant Capital, to, among other things, extend the maturity date of the promissory note to December 31, 2026 and to subordinate the Second Promissory Note in right of payment to the 2026 Notes. Registration Rights Agreement On April 27, 2021, in connection with the issuance of the 2026 Notes, the Company and each of the investors listed on the schedule of buyers entered into a Resale Registration Rights Agreement (the “Registration Rights Agreement”). Pursuant to the terms of the Registration Rights Agreement, the Company is obligated to, among other things, file a registration statement under the Securities Act to register the resale of all Registrable Securities (as defined in the Registration Rights Agreement). Indenture On April 27, 2021, the Company and the Guarantor entered into an indenture (the “2021 Indenture”) by and among NantHealth, the Guarantor and U.S. Bank National Association, as trustee (the “Trustee”), pursuant to which the Company issued the 2026 Notes. The 2026 Notes will bear interest at a rate of 4.50% per year, payable semi-annually on April 15 and October 15 of each year, beginning on October 15, 2021. The 2026 Notes will mature on April 15, 2026, unless earlier repurchased, redeemed or converted. The 2026 Notes are the Company’s general unsecured obligations and are initially guaranteed on a senior unsecured basis by the Guarantor. The initial conversion rate of the 2026 Notes is 259.8753 shares of common stock per $1 principal amount of 2026 Notes (which is equivalent to an initial conversion price of approximately $3.85 per share). The conversion rate will be subject to adjustment upon the occurrence of certain specified events in accordance with the terms of the 2021 Indenture but will not be adjusted for accrued and unpaid interest. Holders of the 2026 Notes may convert all or a portion of their 2026 Notes, in multiples of $1 principal amount, at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the 2026 Notes will be settled in cash, shares of the Company's common stock or any combination thereof at the Company's option. The Company may not redeem the 2026 Notes prior to April 20, 2024. The Company may redeem for cash all or any portion of the 2026 Notes, at its option, on or after April 20, 2024, if the last reported sale price of the common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2026 Notes to be redeemed, plus any accrued and unpaid special interest to, but excluding, the redemption date. No sinking fund is provided for the 2026 Notes, which means that the Company is not required to redeem or retire the 2026 Notes periodically. Upon the occurrence of a fundamental change (as defined in the 2021 Indenture), holders may require the Company to purchase all or a portion of the 2026 Notes in principal amounts of $1 or an integral multiple thereof, for cash at a price equal to 100% of the principal amount of the 2026 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date. For so long as at least $25,000 principal amount of the 2026 Notes are outstanding, the 2021 Indenture restricts the Company or any of its subsidiaries from creating, assuming or incurring any indebtedness owing to any of the Company's affiliates (other than intercompany indebtedness between the Company and its subsidiaries and other than any of the Company's 5.50% Convertible Notes due 2021 or the 2026 Notes held by the Company’s affiliates), or prepaying any such indebtedness, subject to certain exceptions, unless certain conditions described in the 2021 Indenture have been satisfied. The following events are considered “events of default” with respect to the 2026 Notes, which may result in the acceleration of the maturity of the 2026 Notes: (1) the Company defaults in any payment of interest on the 2026 Notes when due and payable and the default continues for a period of 30 days; (2) the Company defaults in the payment of principal on the 2026 Notes when due and payable at the stated maturity, upon redemption, upon any required repurchase, upon declaration of acceleration or otherwise; (3) failure by the Company to comply with its obligation to convert the 2026 Notes in accordance with the 2021 Indenture upon exercise of a holder’s conversion right and such failure continues for a period of five business days; (4) failure by the Company to give a fundamental change notice or notice of a specified corporate transaction when due with respect to the 2026 Notes; (5) failure by the Company to comply with its obligations under the 2021 Indenture with respect to consolidation, merger and sale of assets of the Company; (6) failure by the Company to comply with any of its other agreements contained in the 2026 Notes or the 2021 Indenture, for a period 60 days after written notice from the Trustee or the holders of at least 25% in principal amount of the 2026 Notes then outstanding has been received; (7) default by the Company or any of its significant subsidiaries (as defined in the 2021 Indenture) with respect to any mortgage, agreement or other instrument under which there may be outstanding, or by which there may be secured or evidenced, any indebtedness for money borrowed in excess of $17,500 (or its foreign currency equivalent) in the aggregate of the Company and/or any such subsidiary, whether such indebtedness now exists or shall hereafter be created (i) resulting in such indebtedness becoming or being declared due and payable or (ii) constituting a failure to pay the principal of any such indebtedness when due and payable at its stated maturity, upon required repurchase, upon declaration of acceleration or otherwise, and, in the case of clauses (i) and (ii), such default is not rescinded or annulled or such failure to pay or default shall not have been cured or waived, such acceleration is not rescinded or such indebtedness is not discharged, as the case may be, within 30 days after notice to the Company by the Trustee or to the Company and the Trustee by holders of at least 25% in aggregate principal amount of 2026 Notes then outstanding in accordance with the 2021 Indenture; or (8) certain events of bankruptcy, insolvency, or reorganization of the Company or any of its significant subsidiaries (as defined in the 2021 Indenture). If such an event of default, other than an event of default described in clause (8) above with respect to the Company, occurs and is continuing, the Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2026 Notes by notice to the Company and the Trustee, may, and the Trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2026 Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization involving the Company, 100% of the principal of and accrued and unpaid interest on the 2026 Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest on the 2026 Notes, if any, will be due and payable immediately. Repurchase Offer In connection with the issuance of the 2026 Notes and the amended and restated promissory notes, on April 27, 2021, the Company provided a notice of a fundamental change (as defined in the indenture governing the Company's 5.50% Convertible Notes due 2021) and an offer to repurchase all of the Company's outstanding Convertible Notes. Any Convertible Notes properly tendered pursuant to such offer to purchase shall be purchased on May 25, 2021 (the “Repurchase Date”) at a redemption price of 100% of the principal amount thereof, plus accrued and unpaid interest thereon to, but not including, the Repurchase Date.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of ConsolidationThe accompanying unaudited Consolidated Financial Statements include the accounts of NantHealth and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These interim Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company's financial position and results of operations. In accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X as issued by the Securities and Exchange Commission ("SEC"), these Consolidated Financial Statements do not include all of the information and disclosures required by GAAP for complete financial statements. These Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements for the fiscal year ended December 31, 2020. The results of operations of the entities disposed of are included in the unaudited Consolidated Financial Statements up to the date of disposal and, where appropriate, these operations have been reflected as discontinued operations. The accompanying Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited Consolidated Financial Statements at that date. Assets and liabilities of the discontinued operations are presented separately in the asset and liability sections of the prior period balance sheet. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year.
Use of Estimates	Use of Estimates The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Segment Reporting	Segment Reporting The chief operating decision maker for the Company is its Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, or plans for levels or components below the consolidated unit level. Ac cordingly, management has determined that the Company operates in one reportable segment.
Recently Adopted and Upcoming Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40) . This update simplifies the accounting for convertible instruments by eliminating the cash conversion and beneficial conversion feature models which require separate accounting for embedded conversion features. This update also amends the guidance for the derivatives scope exception for contracts in an entity's own equity to reduce form-over-substance-based accounting conclusions and requires the application of the if-converted method for calculating diluted earnings per share. ASU No. 2020-06 is effective for fiscal periods beginning after December 15, 2023. The Company early adopted ASU 2020-06 on a modified retrospective basis on January 1, 2021. The cumulative effect of the adoption on accumulated deficit and additional paid-in capital was a decrease of $8,572 and $14,318, respectively, on January 1, 2021. Under the new guidance, the Company will record less noncash interest expense going forward as the cash conversion model that was previously applied is now eliminated. Upcoming Accounting Standard Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments , which changes how companies measure credit losses on most financial instruments measured at amortized cost, such as loans, receivables and held-to-maturity debt securities. Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the Company expects to collect over the instrument's contractual life. ASU No. 2016-13 is effective for fiscal periods beginning after December 15, 2022 and must be adopted as a cumulative effect adjustment to retained earnings. Early adoption is permitted. The Company is still evaluating the effects of this ASU. In November 2020, the SEC issued Release No. 33-10890, Amendments to Management's Discussion and Analysis, Selected Financial Data, and Supplementary Financial Information , to modernize, simplify, and enhance certain financial disclosure requirements in Regulation S-K. Mandatory compliance for this SEC release is required for fiscal periods ending on or after August 9, 2021. The Company adopted Item 303(a)(5), Contractual Obligations , which no longer requires the registrant to provide a contractual obligation table. The Company’s adoption of the remaining items is expected to impact the Company's fiscal 2021 Form 10-K disclosures and will not have a material impact on the Consolidated Financial Statements. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not have, nor are believed by management to have, a material impact on the Company's present or future Consolidated Financial Statements.

Discontinued Operations and D_2

Discontinued Operations and Divestitures (Tables)	3 Months Ended
	Mar. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedules of Discontinued Operations	The total gain on sale of the Connected Care Business consisted of the following: Cash received as consideration $ 47,250 Less: Costs to sell (849) Less: Carrying value of net assets sold (14,190) Gain on sale of the Connected Care Business $ 32,211 The operating results of the Company's discontinued operation were as follows: Three Months Ended 2020 Major classes of line items constituting pretax income (loss) of discontinued operations Net revenue $ 1,165 Cost of revenue (467) Selling, general and administrative (524) Research and development (592) Other expense, net (5) Pretax loss from discontinued operations related to major classes of pretax income (loss) (423) Pretax gain on sale of the Connected Care Business 32,211 Total pretax income from discontinued operations 31,788 Benefit from income taxes (223) Total gain from discontinued operations, net of tax $ 32,011 The significant operating and investing cash and noncash items of the discontinued operation included on the Consolidated Statements of Cash Flows were as follows: Three Months Ended 2020 Cash flows from operating activities: Depreciation and amortization $ 10 Gain on sale of the Connected Care Business 32,211 Cash flows from investing activities: Net proceeds from sale of the Connected Care Business $ 46,401 Purchases of property and equipment, including internal-use software 76

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Other Current Assets And Other Current Liabilities [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, Prepaid expenses $ 2,593 $ 2,268 Restricted cash 1,180 238 Other current assets 776 998 Prepaid expenses and other current assets $ 4,549 $ 3,504
Schedule of Accrued and Other Current Liabilities	Accrued and other current liabilities as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, Accrued payroll and related costs $ 8,235 $ 7,247 Operating lease liabilities 1,900 1,900 Other accrued and other current liabilities 5,697 4,828 Accrued and other current liabilities $ 15,832 $ 13,975

Property, Plant and Equipment_2

Property, Plant and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, net	Property, plant and equipment, net as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, Computer equipment and software $ 12,287 $ 12,332 Furniture and equipment 1,168 1,168 Leasehold improvements 4,286 4,282 Property, plant, and equipment, excluding internal-use software, gross 17,741 17,782 Less: Accumulated depreciation and amortization (13,225) (12,837) Property, plant and equipment, excluding internal-use software, net 4,516 4,945 Internal-use software 39,303 38,488 Construction in progress - Internal-use software 1,975 1,616 Less: Accumulated depreciation and amortization, internal-use software (32,935) (31,947) Internal-use software, net 8,343 8,157 Property, plant and equipment, net $ 12,859 $ 13,102

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The Company’s definite-lived intangible assets as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, Customer relationships $ 53,000 $ 53,000 Developed technologies 34,500 34,500 Trade name 3,300 3,300 Installed user base 1,400 1,400 Intangible assets, gross 92,200 92,200 Less: Accumulated amortization (46,463) (44,231) Intangible assets, net $ 45,737 $ 47,969
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated future amortization expense over the next five years and thereafter for the intangible assets that exist as of March 31, 2021 is as follows: Amounts Remainder of 2021 $ 6,697 2022 8,930 2023 4,346 2024 4,283 2025 4,147 2026 3,467 Thereafter 13,867 Total future intangible amortization expense $ 45,737

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	The Company used the following summarized financial information for NantOmics for the three months ended December 31, 2019, to record its equity method losses for the three months ended March 31, 2020: Revenues $ 223 Gross loss (1,163) Loss from operations (3,856) Net loss (1,360) Net loss attributable to NantOmics (1,329)

Convertible Notes (Tables)

Convertible Notes (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Convertible Debt	The following table summarizes how the issuance of the Convertible Notes is reflected in the Company's Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020. Related Party Others Total Balance as of March 31, 2021 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (37) (905) (942) Net carrying amount $ 9,963 $ 96,095 $ 106,058 Balance as of December 31, 2020 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (589) (6,422) (7,011) Net carrying amount $ 9,411 $ 90,578 $ 99,989
Schedule of Interest Expense	The following tables set forth the Company's interest expense recognized in the Company's Consolidated Statements of Operations: Three Months Ended March 31, 2021 Related Party Others Total Accrued coupon interest expense $ 137 $ 1,334 $ 1,471 Amortization of debt discounts 8 76 84 Amortization of deferred financing offering costs 5 234 239 Total convertible notes interest expense $ 150 $ 1,644 $ 1,794 Three Months Ended March 31, 2020 Related Party Others Total Accrued coupon interest expense $ 137 $ 1,334 $ 1,471 Amortization of debt discounts 127 1,238 1,365 Amortization of deferred financing offering costs 3 174 177 Total convertible notes interest expense $ 267 $ 2,746 $ 3,013

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 consisted of the following: March 31, 2021 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Liabilities Bookings Commitment $ 35,114 $ — $ — $ 35,114 December 31, 2020 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Liabilities Bookings Commitment $ 32,651 $ — $ — $ 32,651 Interest make-whole derivative 4 — — 4
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following tables set forth a summary of changes in the fair value of Level 3 liabilities for the three months ended March 31, 2021: December 31, 2020 Transfers in (out) Change in fair value recognized in earnings March 31, 2021 Liabilities Interest make-whole derivative - related party and others $ 4 $ — $ (4) $ — Bookings Commitment 32,651 — 2,463 35,114 $ 32,655 $ — $ 2,459 $ 35,114 Fair Value of Convertible Notes held at amortized cost As of March 31, 2021 and December 31, 2020, the fair value and carrying value of the Company's Convertible Notes were: Fair value Carrying value Face value 5.5% convertible senior notes due December 15, 2021: Balance as of March 31, 2021 Related party $ 9,896 $ 9,963 $ 10,000 Others 95,991 96,095 97,000 $ 105,887 $ 106,058 $ 107,000 Balance as of December 31, 2020 Related party $ 9,553 $ 9,411 $ 10,000 Others 92,660 90,578 97,000 $ 102,213 $ 99,989 $ 107,000

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Operating Lease Maturities	Future minimum lease payments under the Company's operating leases at March 31, 2021 were: Maturity Analysis Amounts Remainder of 2021 $ 2,147 2022 2,683 2023 2,691 2024 2,537 2025 684 2026 613 Thereafter 1,087 Total future minimum lease payments 12,442 Less: imputed interest (2,819) Total $ 9,623 As reported in the Consolidated Balance Sheet Accrued and other current liabilities $ 1,900 Operating lease liabilities 7,723 $ 9,623

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The following table reflects the components of stock-based compensation expense recognized in the Company's Consolidated Statements of Operations: Three Months Ended 2021 2020 Phantom units: Cost of revenue $ — $ 16 Selling, general and administrative — 9 Research and development — 17 Total phantom units stock-based compensation expense — 42 Stock options: Cost of revenue 42 15 Selling, general and administrative 698 237 Research and development 98 24 Total stock options stock-based compensation expense 838 276 Restricted stock units: Cost of revenue — 7 Selling, general and administrative 49 389 Research and development — 18 Total restricted stock units stock-based compensation expense 49 414 Discontinued operations — (79) Total stock-based compensation expense 887 653 Amount capitalized to internal-use software 25 19 Total stock-based compensation cost $ 912 $ 672
Activity related to unvested stock options	The following table summarizes the activity related to stock options during the three months ended March 31, 2021: Number of Shares Weighted-Average Exercise Price Stock options outstanding - December 31, 2020 10,025,124 $ 2.19 Exercised (103,900) $ 0.55 Forfeited (242,500) $ 3.05 Stock options outstanding - March 31, 2021 9,678,724 $ 2.18 Stock options exercisable - March 31, 2021 2,707,474 $ 0.57
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes the activity related to the unvested restricted stock units during the three months ended March 31, 2021: Number of Units Weighted-Average Grant Date Fair Value Unvested restricted stock units outstanding - December 31, 2020 253,308 $ 1.64 Vested (59,853) $ 1.81 Unvested restricted stock units outstanding - March 31, 2021 193,455 $ 1.59

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net (loss) income per share of common stock attributable to NantHealth for the three months ended March 31, 2021 and 2020: Three Months Ended 2021 2020 Common Stock Common Stock Net (loss) income per share numerator: Net loss from continuing operations $ (15,503) $ (8,940) Net loss attributable to noncontrolling interests (91) — Net loss from continuing operations attributable to NantHealth (15,412) (8,940) Income from discontinued operations attributable to NantHealth 4 32,005 Net (loss) income attributable to NantHealth for basic and diluted net loss per share $ (15,408) $ 23,065 Weighted-average shares for basic and diluted net (loss) income per share 111,319,061 110,619,780 Basic and diluted net (loss) income per share attributable to NantHealth: Continuing operations - common stock $ (0.14) $ (0.08) Discontinued operations - common stock $ — $ 0.29 Total net (loss) income per share - common stock $ (0.14) $ 0.21
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following number of potential common shares at the end of each period were excluded from the calculation of diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive for the periods presented: March 31, 2021 2020 Unvested phantom units — 115,108 Unvested restricted stock units 193,455 874,019 Unexercised stock options 9,678,724 5,545,724 Convertible notes 8,815,655 8,815,655

Related Party Disclosures (Tabl

Related Party Disclosures (Tables)	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Assignment of OpenNMS	Amounts Total cash consideration $ 5,577 Assets and liabilities of OpenNMS at assignment: Cash and cash equivalents 102 Goodwill 1,026 Intangible asset, net 4,553 Other assets 1,097 Other liabilities assumed (1,227) Net assets acquired at assignment 5,551 Noncontrolling interests (503) Recorded as distribution from additional paid-in capital $ 529

Summary of Significant Accoun_3

Summary of Significant Accounting Policies Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)activitysegment	Dec. 31, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)
New Accounting Pronouncement, Early Adoption [Line Items]
Number of business activities | activity	1
Number of reportable segments | segment	1
Cumulative effect of accounting standard	$ (131,641)	$ (111,400)	$ (33,591)	$ (57,136)
Accumulated Deficit
New Accounting Pronouncement, Early Adoption [Line Items]
Cumulative effect of accounting standard	(1,010,046)	(1,003,210)	(923,819)	(946,884)
Additional Paid-In Capital
New Accounting Pronouncement, Early Adoption [Line Items]
Cumulative effect of accounting standard	$ 878,241	891,583	$ 890,623	$ 889,955
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncement, Early Adoption [Line Items]
Cumulative effect of accounting standard		(5,746)
Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit
New Accounting Pronouncement, Early Adoption [Line Items]
Cumulative effect of accounting standard		8,572
Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit | Accounting Standard Updated 2020-06
New Accounting Pronouncement, Early Adoption [Line Items]
Cumulative effect of accounting standard		8,572
Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-In Capital
New Accounting Pronouncement, Early Adoption [Line Items]
Cumulative effect of accounting standard		(14,318)
Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-In Capital | Accounting Standard Updated 2020-06
New Accounting Pronouncement, Early Adoption [Line Items]
Cumulative effect of accounting standard		$ (14,318)

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue recognized	$ 538	$ 1,828
Capitalized contract cost	1,024		$ 1,321
Amortization of contract costs	$ 160	$ 242

Revenue Recognition Performance

Revenue Recognition Performance Obligations (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Revenue from Contract with Customer [Abstract]
Unfulfilled performance obligations	$ 2,543
Description of timing of performance obligations	unfulfilled performance obligations that are expected to be fulfilled within 10 years.

Discontinued Operations and D_3

Discontinued Operations and Divestitures - Narrative (Details) $ in Thousands	Feb. 03, 2020USD ($)
Connected Care Business | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received as consideration	$ 47,250

Discontinued Operations and D_4

Discontinued Operations and Divestitures - Schedule of Gain on Sale of Connected Care Business (Details) - Connected Care Business - Discontinued Operations, Disposed of by Sale - USD ($) $ in Thousands	Feb. 03, 2020	Mar. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received as consideration	$ 47,250
Less: Costs to sell	(849)
Less: Carrying value of net assets sold	$ (14,190)
Gain on sale of the Connected Care Business		$ 32,211

Discontinued Operations and D_5

Discontinued Operations and Divestitures - Schedule of Operating Results of Discontinued Operations (Details) - Connected Care Business - Discontinued Operations, Disposed of by Sale $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 1,165
Cost of revenue	(467)
Selling, general and administrative	(524)
Research and development	(592)
Other expense, net	(5)
Pretax loss from discontinued operations related to major classes of pretax income (loss)	(423)
Gain on sale of the Connected Care Business	32,211
Total pretax income from discontinued operations	31,788
Benefit from income taxes	(223)
Total gain from discontinued operations, net of tax	$ 32,011

Discontinued Operations and D_6

Discontinued Operations and Divestitures - Schedule of Significant Operating and Investing Cash and Noncash Items (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	[1]
Cash flows from investing activities:
Net proceeds from sale of the Connected Care Business	$ 0	$ 46,401
Connected Care Business | Discontinued Operations, Disposed of by Sale
Cash flows from operating activities:
Depreciation and amortization	10
Gain on sale of the Connected Care Business	32,211
Cash flows from investing activities:
Net proceeds from sale of the Connected Care Business	46,401
Purchases of property and equipment, including internal-use software	$ 76
[1]	The statements for the three months ended March 31, 2020 include the Connected Care Business (see Note 4).

Accounts Receivable, net (Detai

Accounts Receivable, net (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Receivables [Abstract]
Allowance for doubtful accounts	$ 33	$ 44

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Other Current Assets And Other Current Liabilities [Abstract]
Prepaid expenses	$ 2,593	$ 2,268
Restricted cash	1,180	238
Other current assets	776	998
Prepaid expenses and other current assets	$ 4,549	$ 3,504

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Other Current Assets And Other Current Liabilities [Abstract]
Accrued payroll and related costs	$ 8,235	$ 7,247
Operating lease liabilities	1,900	1,900
Other accrued and other current liabilities	5,697	4,828
Accrued and other current liabilities	$ 15,832	$ 13,975

Property, Plant and Equipment_3

Property, Plant and Equipment, net Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, net	$ 12,859		$ 13,102
Depreciation expense	1,411	$ 2,008
Amount capitalized to internal use software	890	1,210
Property, plant, and equipment, excluding internal-use software, gross
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	17,741		17,782
Less: Accumulated depreciation and amortization	(13,225)		(12,837)
Property, plant, and equipment, net	4,516		4,945
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	12,287		12,332
Furniture and equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	1,168		1,168
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	4,286		4,282
Internal-use software
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	39,303		38,488
Less: Accumulated depreciation and amortization	(32,935)		(31,947)
Construction in progress - Internal-use software	1,975		1,616
Property, plant, and equipment, net	8,343		$ 8,157
Depreciation expense	$ 989	$ 1,635

Intangible Assets, net Schedule

Intangible Assets, net Schedule of Definite-Lived Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 92,200	$ 92,200
Less: Accumulated amortization	(46,463)	(44,231)
Intangible assets, net	45,737	47,969
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	53,000	53,000
Developed technologies
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	34,500	34,500
Trade name
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	3,300	3,300
Installed user base
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,400	$ 1,400

Intangible Assets, net Narrativ

Intangible Assets, net Narrative (Details) - USD ($) $ in Thousands	Jul. 22, 2020	Mar. 31, 2021	Mar. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Amortization expense		$ 2,232	$ 2,010
OpenNMS Assignment
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible asset acquired in assignment	$ 5,200
Accumulated amortization of intangible asset	$ (647)
Minimum | OpenNMS Assignment
Finite-Lived Intangible Assets [Line Items]
Estimated lives of definite-lived intangible assets	4 years
Maximum | OpenNMS Assignment
Finite-Lived Intangible Assets [Line Items]
Estimated lives of definite-lived intangible assets	6 years

Intangible Assets, net Schedu_2

Intangible Assets, net Schedule of Future Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2021	$ 6,697
2022	8,930
2023	4,346
2024	4,283
2025	4,147
2026	3,467
Thereafter	13,867
Intangible assets, net	$ 45,737	$ 47,969

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Jul. 22, 2020
Acquired Indefinite-lived Intangible Assets [Line Items]
Goodwill	$ 98,333	$ 98,333
Discontinued operations, goodwill	$ 18,623	$ 18,623
OpenNMS Assignment | Equity Method Investee
Acquired Indefinite-lived Intangible Assets [Line Items]
Goodwill			$ 1,026

Investments Narrative (Details)

Investments Narrative (Details) - USD ($) $ in Thousands	Feb. 28, 2018	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020		May 31, 2018	Dec. 31, 2015	Dec. 31, 2020	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Loss from related party equity method investment		$ 0		$ 1,784	[1]
NantOmics
Schedule of Equity Method Investments [Line Items]
Number of A-2 units purchased (in shares)	9,088,362					564,779	169,074,539
Aggregate purchase price							$ 250,774
Ownership percentage						13.58%	14.28%
Difference between the carrying value and equity, intangible assets									$ 28,195
Difference between the carrying value and equity, goodwill									$ 14,382
Other-than temporary impairment			$ 28,227
Loss from related party equity method investment		$ 0		$ 1,784
Investment in related party								$ 0
[1]	The statements for the three months ended March 31, 2020 include the Connected Care Business (see Note 4).

Investments Summarized Financia

Investments Summarized Financial Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020		Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Gross loss	$ 9,127	$ 10,984
Loss from operations	(9,373)	(5,860)
Net loss	(15,499)	23,065	[1]
Net loss attributable to NantOmics	$ (15,408)	$ 23,065
NantOmics
Schedule of Equity Method Investments [Line Items]
Revenues				$ 223
Gross loss				(1,163)
Loss from operations				(3,856)
Net loss				(1,360)
Net loss attributable to NantOmics				$ (1,329)
[1]	The statements for the three months ended March 31, 2020 include the Connected Care Business (see Note 4).

Convertible Notes - Narrative (

Convertible Notes - Narrative (Details)	Apr. 13, 2021USD ($)	Dec. 21, 2016USD ($)day$ / shares	Dec. 31, 2016USD ($)	Mar. 31, 2021USD ($)$ / shares	Apr. 27, 2021	Jan. 01, 2021USD ($)	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Remaining life of convertible notes				9 months
Common stock, par value (usd per share) | $ / shares				$ 0.0001			$ 0.0001
Cambridge Purchase Agreement
Debt Instrument [Line Items]
Convertible notes payable				$ 10,000,000
Cambridge Purchase Agreement | Subsequent Event
Debt Instrument [Line Items]
Amount of convertible debt converted	$ 5,000,000
Highbridge Capital Management
Debt Instrument [Line Items]
Convertible notes payable				36,945,000
Convertible Debt
Debt Instrument [Line Items]
Face value of debt		$ 107,000	$ 107,000,000	107,000,000			$ 107,000,000
Interest rate on debt		5.50%						5.50%
Proceeds from issuance of convertible notes, net of offering costs			102,714,000
Initial purchasers' discount and debt issuance costs		$ 4,286,000						$ 4,286,000
Conversion rate of convertible debt		82.3893
Conversion price of convertible debt (usd per share) | $ / shares		$ 12.14
Threshold of trading days | day		20
Threshold consecutive trading days | day		30
Threshold percentage of stock price trigger		120.00%
Business day period trading price evaluated | day		5
Number of consecutive trading days trading price evaluated | day		5
Threshold percentage of principal amount		98.00%
Percent of principal		100.00%
Period after conversion date to trigger interest make-whole feature		3 years
Total liability component of convertible notes on date of issuance		$ 83,079,000
Interest make-whole derivative on date of issuance		1,499,000
Carrying value of convertible notes on date of issuance		81,580,000		$ 106,058,000			$ 99,989,000
Conversion option reported in equity as additional paid-in capital		23,921,000
Purchasers' initial discount		972,000
Deferred financing offering costs		$ 3,314,000
Effective interest rate		6.78%
Convertible Debt | Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Carrying value of convertible notes on date of issuance						$ 5,746,000
Convertible Debt | Subsequent Event
Debt Instrument [Line Items]
Interest rate on debt					5.50%
Convertible Debt | Initial Purchasers Agreement
Debt Instrument [Line Items]
Face value of debt								90,000,000
Proceeds from issuance of convertible notes, net of offering costs			92,797,000
Convertible Debt | Cambridge Purchase Agreement
Debt Instrument [Line Items]
Face value of debt								10,000,000
Proceeds from issuance of convertible notes, net of offering costs			$ 9,917,000
Convertible Debt | Pursuant to the exercise of the overallotment by the Initial Purchasers
Debt Instrument [Line Items]
Face value of debt								$ 7,000,000
Convertible Debt | Measurement Input, Discount Rate
Debt Instrument [Line Items]
Discount rate		2.00%

Convertible Notes - Summary of

Convertible Notes - Summary of Issuance of Convertible Debt (Details) - Convertible Debt - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Dec. 21, 2016
Debt Instrument [Line Items]
Gross proceeds	$ 107,000	$ 107,000
Unamortized debt discounts and deferred financing offering costs	(942)	(7,011)
Net carrying amount	106,058	99,989	$ 81,580
Related Party
Debt Instrument [Line Items]
Gross proceeds	10,000	10,000
Unamortized debt discounts and deferred financing offering costs	(37)	(589)
Net carrying amount	9,963	9,411
Others
Debt Instrument [Line Items]
Gross proceeds	97,000	97,000
Unamortized debt discounts and deferred financing offering costs	(905)	(6,422)
Net carrying amount	$ 96,095	$ 90,578

Convertible Notes - Interest Ex

Convertible Notes - Interest Expense Incurred (Details) - Convertible Debt - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Debt Instrument [Line Items]
Accrued coupon interest expense	$ 1,471	$ 1,471
Amortization of debt discounts	84	1,365
Amortization of deferred financing offering costs	239	177
Total convertible notes interest expense	1,794	3,013
Related Party
Debt Instrument [Line Items]
Accrued coupon interest expense	137	137
Amortization of debt discounts	8	127
Amortization of deferred financing offering costs	5	3
Total convertible notes interest expense	150	267
Others
Debt Instrument [Line Items]
Accrued coupon interest expense	1,334	1,334
Amortization of debt discounts	76	1,238
Amortization of deferred financing offering costs	234	174
Total convertible notes interest expense	$ 1,644	$ 2,746

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Liabilities
Bookings Commitment	$ 35,114	$ 32,651
Interest make-whole derivative		4
Quoted price in active markets for identical assets (Level 1)
Liabilities
Bookings Commitment	0	0
Interest make-whole derivative		0
Significant other observable inputs (Level 2)
Liabilities
Bookings Commitment	0	0
Interest make-whole derivative		0
Significant unobservable inputs (Level 3)
Liabilities
Bookings Commitment	$ 35,114	32,651
Interest make-whole derivative		$ 4

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($)	Dec. 30, 2017	Dec. 21, 2016	Dec. 31, 2016	Mar. 31, 2021	Jun. 30, 2020	Dec. 31, 2020
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Minimum booking commitments	$ 95,000,000
Bookings commitment period	10 years			10 years
Bookings commitment annual minimum	$ 500,000
Booking commitments current annual accrual				$ 1,200,000		$ 1,200,000
Percentage of shortfall payable				70.00%
Commission percentage				30.00%
Impact of adverse change in discount rate				$ 4,511,000
Sensitivity analysis, adverse change in discount rate				2.00%
Convertible Debt
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Face value of debt		$ 107,000	$ 107,000,000	$ 107,000,000		107,000,000
Period to lapse to trigger interest make-whole feature			1 year
Threshold period used to compute interest payment			3 years
Convertible Debt | Measurement Input, Discount Rate
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate		2.00%
Convertible Debt | Convertible Debt, Related Party
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Face value of debt			$ 10,000,000	$ 10,000,000		$ 10,000,000
Minimum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cost of debt range used for discounting				8.00%	10.00%
Maximum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cost of debt range used for discounting				10.00%	11.00%
Derivative Financial Instruments, Liabilities | Measurement Input, Discount Rate
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate			2.00%

Fair Value Measurements - Chang

Fair Value Measurements - Changes in the Fair Value of Level 3 Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 32,655
Transfers in (out)	0
Change in fair value	2,459
Ending balance	35,114
Interest make-whole derivative - related party and others
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	4
Transfers in (out)	0
Change in fair value	(4)
Ending balance	0
Bookings Commitment
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	32,651
Transfers in (out)	0
Change in fair value	2,463
Ending balance	$ 35,114

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Debt (Details) - Convertible Debt - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2016	Dec. 21, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Face value	$ 107,000,000	$ 107,000,000	$ 107,000,000	$ 107,000
Fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	105,887,000	102,213,000
Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	106,058,000	99,989,000
Related Party
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Face value	10,000,000	10,000,000	$ 10,000,000
Related Party | Fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	9,896,000	9,553,000
Related Party | Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	9,963,000	9,411,000
Others
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Face value	97,000,000	97,000,000
Others | Fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	95,991,000	92,660,000
Others | Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	$ 96,095,000	$ 90,578,000

Leases Operating Lease Maturity

Leases Operating Lease Maturity Analysis (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Remainder of 2021	$ 2,147
2022	2,683
2023	2,691
2024	2,537
2025	684
2026	613
Thereafter	1,087
Total future minimum lease payments	12,442
Less: imputed interest	(2,819)
Total	9,623
As reported in the Consolidated Balance Sheet
Accrued and other current liabilities	1,900	$ 1,900
Operating lease liabilities	$ 7,723	$ 8,170

Commitments and Contingencies (

Commitments and Contingencies (Details)	Oct. 23, 2019USD ($)	Apr. 30, 2018claim	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2017	Dec. 31, 2016USD ($)	Dec. 21, 2016USD ($)	Jan. 04, 2016USD ($)
Related Party Transaction [Line Items]
Related party promissory note			$ 112,666,000	$ 112,666,000
Unconditional purchase obligations in year one				500,000
Unconditional purchase obligations in year two				600,000
Unconditional purchase obligations in year three				100,000
Payments for amounts purchased under unconditional purchase obligations			111,000
Claims filed | claim		2
Insurance recoveries			98,000	253,000
Securities and Derivative Litigation Member
Related Party Transaction [Line Items]
Litigation settlement	$ 16,500,000
Affiliated Entity | Promissory Notes With NantCapital
Related Party Transaction [Line Items]
Related party promissory note			145,526,000	143,756,000				$ 112,666,000
Convertible Debt
Related Party Transaction [Line Items]
Face value of debt			$ 107,000,000	$ 107,000,000		$ 107,000,000	$ 107,000
Interest rate on debt					5.50%		5.50%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Provision for (benefit from) income taxes	$ 8	$ (93)
Effective tax rate	(0.05%)	1.05%

Stockholders_ Equity (Details)

Stockholders’ Equity (Details)	3 Months Ended
	Mar. 31, 2021vote$ / sharesshares	Dec. 31, 2020$ / sharesshares
Equity [Abstract]
Common stock authorized (shares)	750,000,000	750,000,000
Common stock, par value (usd per share) | $ / shares	$ 0.0001	$ 0.0001
Preferred stock authorized (shares)	20,000,000
Preferred stock, par value (usd per share) | $ / shares	$ 0.0001
Number of votes per unit held | vote	1
Preferred stock outstanding (in shares)	0	0

Stock-Based Compensation Compon

Stock-Based Compensation Components of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Amount capitalized to internal-use software	$ 25	$ 19
Total stock-based compensation cost	912	672
Phantom units:
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	0	42
Phantom units: | Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	0	16
Phantom units: | Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	0	9
Phantom units: | Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	0	17
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	838	276
Stock options | Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	42	15
Stock options | Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	698	237
Stock options | Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	98	24
Restricted stock units:
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	49	414
Restricted stock units: | Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	0	7
Restricted stock units: | Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	49	389
Restricted stock units: | Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	0	18
Discontinued operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	0	(79)
Continuing and Discontinued Operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 887	$ 653

Stock-Based Compensation Narrat

Stock-Based Compensation Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)shares
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock based compensation	$ 10,111
Weighted average period of recognition for stock based compensation expense recognition (in years)	2 years 6 months
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock based compensation	$ 227
Weighted average period of recognition for stock based compensation expense recognition (in years)	6 months
The 2016 Equity Incentive Plan | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued (in shares) | shares	59,853

Stock-Based Compensation Activi

Stock-Based Compensation Activity of Stock based Compensation Units (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Number of  Shares
Stock options outstanding, beginning balance (in shares) | shares	10,025,124
Exercised (in shares) | shares	(103,900)
Forfeited (in shares) | shares	(242,500)
Stock options outstanding, ending balance (in shares) | shares	9,678,724
Stock options exercisable (in shares) | shares	2,707,474
Weighted-Average  Exercise Price
Stock options outstanding, beginning balance (in dollars per share) | $ / shares	$ 2.19
Exercised (in dollars per share) | $ / shares	0.55
Forfeited (in dollars per share) | $ / shares	3.05
Stock options outstanding, ending balance (in dollars per share) | $ / shares	2.18
Stock options exercisable (in dollars per share) | $ / shares	$ 0.57

Stock-Based Compensation Acti_2

Stock-Based Compensation Activity of Restricted Stock Units (Details) - Restricted Stock Units - $ / shares	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested units outstanding, beginning balance (in units)	253,308
Vested (in units)	(59,853)
Unvested units outstanding, ending balance (in units)	193,455
Weighted-Average Grant Date Fair Value
Unvested restricted stock units outstanding, ending balance (in dollars per unit)	$ 1.59	$ 1.64
Vested (in dollars per unit)	1.81
Unvested restricted stock units outstanding, beginning balance (in dollars per unit)	$ 1.59	$ 1.64

Net Income (Loss) Per Share Rec

Net Income (Loss) Per Share Reconciliations of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net (loss) income per share numerator:
Net loss from continuing operations	$ (15,503)	$ (8,940)
Net loss attributable to noncontrolling interests	(91)	0
Net loss from continuing operations attributable to NantHealth	(15,412)	(8,940)
Income from discontinued operations attributable to NantHealth	4	32,005
Net (loss) income attributable to NantHealth	$ (15,408)	$ 23,065
Weighted Average Number of Shares
Weighted-average shares for basic net income (loss) per share (in shares)	111,319,061	110,619,780
Basic and diluted net (loss) income per share attributable to NantHealth:
Continuing operations - common stock (in dollars per share)	$ (0.14)	$ (0.08)
Discontinued operations - common stock (in dollars per share)	0	0.29
Total net income (loss) per share - common stock (in dollars per share)	$ (0.14)	$ 0.21

Net Income (Loss) Per Share Ant

Net Income (Loss) Per Share Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Unvested phantom units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	115,108
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	193,455	874,019
Unexercised stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	9,678,724	5,545,724
Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	8,815,655	8,815,655

Related Party Transactions (Det

Related Party Transactions (Details)

Apr. 13, 2021USD ($)

Dec. 31, 2020USD ($)$ / shares

Jul. 22, 2020USD ($)shares

Jun. 01, 2016USD ($)shares

Mar. 08, 2016USD ($)

Jan. 22, 2016USD ($)

Jan. 04, 2016USD ($)$ / shares

Jun. 19, 2015USD ($)termtest

Mar. 31, 2021USD ($)$ / shares

Mar. 31, 2020USD ($)

Dec. 31, 2016USD ($)

Dec. 21, 2016USD ($)

Dec. 15, 2016USD ($)

Related Party Transaction [Line Items]

Related party receivables

$ 1,854,000

$ 1,848,000

Related party payables, net of receivables balances including related party liabilities

$ 35,329,000

$ 36,952,000

Common stock, par value (usd per share) | $ / shares

$ 0.0001

$ 0.0001

Related party promissory note

$ 112,666,000

$ 112,666,000

OpenNMS Assignment

Related Party Transaction [Line Items]

Finite lived intangible asset acquired in assignment

$ 5,200,000

Convertible Debt

Related Party Transaction [Line Items]

Face value of debt

107,000,000

107,000,000

$ 107,000,000

$ 107,000

Equity Method Investee | OpenNMS Assignment

Related Party Transaction [Line Items]

Percentage of voting interest acquired

91.00%

Cash paid in business acquisition

$ 5,577,000

Percentage owned by noncontrolling interest

9.00%

Useful life of finite-lived intangible assets

5 years 10 months 24 days

Finite lived intangible asset acquired in assignment

$ 4,553,000

Equity Method Investee | OpenNMS Assignment | Call Option

Related Party Transaction [Line Items]

Cash payment for purchase of business

$ 278,000

Number of shares issued in acquisition (in shares) | shares

56,769

Equity Method Investee | OpenNMS Assignment | Developed technology

Related Party Transaction [Line Items]

Finite lived intangible asset acquired in assignment

$ 2,500,000

Estimated lives of definite-lived intangible assets

6 years

Equity Method Investee | OpenNMS Assignment | Installed user base

Related Party Transaction [Line Items]

Finite lived intangible asset acquired in assignment

$ 1,400,000

Estimated lives of definite-lived intangible assets

6 years

Equity Method Investee | OpenNMS Assignment | Customer relationships

Related Party Transaction [Line Items]

Finite lived intangible asset acquired in assignment

$ 1,000,000

Estimated lives of definite-lived intangible assets

6 years

Equity Method Investee | OpenNMS Assignment | Trade name

Related Party Transaction [Line Items]

Finite lived intangible asset acquired in assignment

$ 300,000

Estimated lives of definite-lived intangible assets

4 years

Receivable from Ziosoft KK related to sale of Qi Imaging | Affiliated Entity

Related Party Transaction [Line Items]

Related party payables, net of receivables balances including related party liabilities

1,477,000

1,477,000

Reseller agreement

Related Party Transaction [Line Items]

Assignment agreement term

5 years 6 months

Reseller agreement | Equity Method Investee

Related Party Transaction [Line Items]

Number of renewals | term

3

Renewal term

3 years

Number of tests to qualify for first renewal option | test

300,000

Number of tests to qualify for second renewal option | test

570,000

Number of tests to qualify for third renewal option | test

760,000

Annual minimum fees, tier one

$ 2,000,000

Related party payables

3,000

0

Cost of revenue

0

$ 36,000

Cambridge Purchase Agreement | Affiliated Entity | Convertible Debt

Related Party Transaction [Line Items]

Face value of debt

$ 10,000,000

Accrued and unpaid interest on convertible notes

24,000

162,000

Cambridge Purchase Agreement | Affiliated Entity | Convertible Debt | Subsequent Event

Related Party Transaction [Line Items]

Amount of convertible debt converted

$ 5,000,000

Liquid Tumor Profiling Services Agreement

Related Party Transaction [Line Items]

Related party receivables

110,000

110,000

Revenue from related parties

0

Promissory Notes With NantCapital | Affiliated Entity

Related Party Transaction [Line Items]

Accrued and unpaid interest on convertible notes

31,090,000

32,860,000

Related party promissory note

$ 143,756,000

$ 112,666,000

145,526,000

Interest bearing on related promissory note

5.00%

Per share price of stock shares to repay debt (usd per share) | $ / shares

$ 18.6126

Per share price of shares to settle debt (usd per share) | $ / shares

$ 1.484

Promissory Notes With NantOmics | Equity Method Investee

Related Party Transaction [Line Items]

Related party promissory note

$ 20,000,000

0

Interest bearing on related promissory note

5.00%

Additional advance on related party promissory note

$ 20,000,000

Amount of principal and interest under promissory note converted to shares

$ 40,590,000

Number of shares related party promissory note converted (in shares) | shares

2,899,297

Promissory Note 5.50%, Due December 31, 2023 | Affiliated Entity

Related Party Transaction [Line Items]

Interest bearing on related promissory note

5.50%

Maximum commitment available on promissory note

$ 125,000,000

Advances made on note

$ 0

0

NantWorks | Shared services agreement | Affiliated Entity

Related Party Transaction [Line Items]

Income from related parties

$ 106,000

Net selling, general, and administrative service expenses incurred related to services provided by related parties

$ 486,000

Related Party Transactions - Op

Related Party Transactions - Open NMS Assignment (Details) - USD ($) $ in Thousands	Jul. 22, 2020	Mar. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Goodwill		$ 98,333	$ 98,333
OpenNMS Assignment
Related Party Transaction [Line Items]
Intangible asset, net	$ 5,200
OpenNMS Assignment | Equity Method Investee
Related Party Transaction [Line Items]
Total cash consideration	5,577
Cash and cash equivalents	102
Goodwill	1,026
Intangible asset, net	4,553
Other assets	1,097
Other liabilities assumed	(1,227)
Net assets acquired at assignment	5,551
Noncontrolling interests	(503)
Recorded as distribution from additional paid-in capital	$ 529

Subsequent Events (Details)

Subsequent Events (Details)	Apr. 27, 2021USD ($)day$ / sharesshares	Apr. 13, 2021USD ($)	Dec. 21, 2016USD ($)day$ / shares	Mar. 31, 2021USD ($)$ / shares	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Subsequent Event [Line Items]
Common stock, par value (usd per share) | $ / shares				$ 0.0001	$ 0.0001
Convertible Debt
Subsequent Event [Line Items]
Face value			$ 107,000	$ 107,000,000	$ 107,000,000		$ 107,000,000
Interest rate on debt			5.50%			5.50%
Conversion price of convertible debt (usd per share) | $ / shares			$ 12.14
Threshold percentage of stock price trigger			120.00%
Threshold of trading days | day			20
Threshold consecutive trading days | day			30
Percent of principal			100.00%
Cambridge Purchase Agreement
Subsequent Event [Line Items]
Convertible notes payable				10,000,000
Cambridge Purchase Agreement | Convertible Debt
Subsequent Event [Line Items]
Face value						$ 10,000,000
Highbridge Capital Management
Subsequent Event [Line Items]
Convertible notes payable				$ 36,945,000
Subsequent Event | Convertible Debt
Subsequent Event [Line Items]
Interest rate on debt	5.50%
Redemption price as a percentage of principal	100.00%
Subsequent Event | 4.50% Convertible Senior Notes Due 2026
Subsequent Event [Line Items]
Interest rate on debt	4.50%
Subsequent Event | 4.50% Convertible Senior Notes Due 2026 | Convertible Debt
Subsequent Event [Line Items]
Face value	$ 137,500,000
Interest rate on debt	4.50%
Proceeds from issuance of notes	$ 137,382,000
Debt issuance costs	$ 118,000
Shares converted per dollar (in shares) | shares	259.8753
Conversion price of convertible debt (usd per share) | $ / shares	$ 3.85
Threshold percentage of stock price trigger	130.00%
Threshold of trading days | day	20
Threshold consecutive trading days | day	30
Redemption price as a percentage of principal	100.00%
Percent of principal	100.00%
Principal outstanding to restrict future indebtedness	$ 25,000
Number of days interest payments are in default | day	30
Number of days after written notice of failure to comply | day	60
Percentage of debt holders	25.00%
Dollar amount of maximum default	$ 17,500,000
Number of days in which to rescind or annull failure to pay or default | day	30
Subsequent Event | 4.50% Convertible Senior Notes Due 2026 | Convertible Debt | Nant Capital
Subsequent Event [Line Items]
Proceeds from issuance of notes	$ 62,500,000
Subsequent Event | 4.50% Convertible Senior Notes Due 2026 | Convertible Debt | Highbridge Capital Management
Subsequent Event [Line Items]
Proceeds from issuance of notes	$ 74,882,000
Subsequent Event | Cambridge Purchase Agreement
Subsequent Event [Line Items]
Amount of convertible debt converted		$ 5,000,000